WO2010144055A1 - Novel compounds and uses thereof - Google Patents
Novel compounds and uses thereof Download PDFInfo
- Publication number
- WO2010144055A1 WO2010144055A1 PCT/SG2010/000216 SG2010000216W WO2010144055A1 WO 2010144055 A1 WO2010144055 A1 WO 2010144055A1 SG 2010000216 W SG2010000216 W SG 2010000216W WO 2010144055 A1 WO2010144055 A1 WO 2010144055A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- carbon
- och
- nucleophile
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 174
- 239000012038 nucleophile Substances 0.000 claims abstract description 38
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 24
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000011593 sulfur Substances 0.000 claims abstract description 20
- 125000004429 atom Chemical group 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 11
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 6
- 125000000101 thioether group Chemical group 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 43
- 239000002537 cosmetic Substances 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 230000036542 oxidative stress Effects 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- -1 health care Substances 0.000 description 84
- 230000003078 antioxidant effect Effects 0.000 description 66
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical class COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- 238000003556 assay Methods 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 31
- 239000000047 product Substances 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 229960002504 capsaicin Drugs 0.000 description 19
- 235000017663 capsaicin Nutrition 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 16
- 239000003963 antioxidant agent Substances 0.000 description 15
- 235000006708 antioxidants Nutrition 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 10
- 238000002784 cytotoxicity assay Methods 0.000 description 10
- 231100000263 cytotoxicity test Toxicity 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000001590 oxidative effect Effects 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000006866 deterioration Effects 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 7
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000012948 isocyanate Chemical group 0.000 description 5
- 150000002513 isocyanates Chemical group 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 231100001083 no cytotoxicity Toxicity 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241001247145 Sebastes goodei Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005035 acylthio group Chemical group 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical group N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 125000005291 haloalkenyloxy group Chemical group 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000004476 heterocycloamino group Chemical group 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004971 nitroalkyl group Chemical group 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- 125000005499 phosphonyl group Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- 235000021081 unsaturated fats Nutrition 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical class CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 0 *C(*Cc1ccccc1)=N Chemical compound *C(*Cc1ccccc1)=N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GJDRKHHGPHLVNI-UHFFFAOYSA-N 2,6-ditert-butyl-4-(diethoxyphosphorylmethyl)phenol Chemical compound CCOP(=O)(OCC)CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GJDRKHHGPHLVNI-UHFFFAOYSA-N 0.000 description 1
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 1
- OSNVTFATVNTMGM-UHFFFAOYSA-N 2-(3,5-dicyclohexyl-4-hydroxyphenyl)propanoic acid Chemical compound OC=1C(C2CCCCC2)=CC(C(C(O)=O)C)=CC=1C1CCCCC1 OSNVTFATVNTMGM-UHFFFAOYSA-N 0.000 description 1
- QLMGIWHWWWXXME-UHFFFAOYSA-N 2-(3,5-ditert-butyl-4-hydroxyphenyl)acetic acid Chemical compound CC(C)(C)C1=CC(CC(O)=O)=CC(C(C)(C)C)=C1O QLMGIWHWWWXXME-UHFFFAOYSA-N 0.000 description 1
- FANGQVKSFHFPBY-UHFFFAOYSA-N 2-(3,5-ditert-butyl-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FANGQVKSFHFPBY-UHFFFAOYSA-N 0.000 description 1
- TWYIRJIBTNKLMI-UHFFFAOYSA-N 2-(3-tert-butyl-4-hydroxy-5-methylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC(C)=C(O)C(C(C)(C)C)=C1 TWYIRJIBTNKLMI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- GHLZUHZBBNDWHW-UHFFFAOYSA-N CCCCCCCCC(N)=O Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 1
- XSVGGJOSGWUVMZ-UHFFFAOYSA-N CCCCCCCCNC(Cc(cc(cc1)NC)c1O)=O Chemical compound CCCCCCCCNC(Cc(cc(cc1)NC)c1O)=O XSVGGJOSGWUVMZ-UHFFFAOYSA-N 0.000 description 1
- BLNSOWYVRUSCDI-UHFFFAOYSA-N CCCCCCCCNC(Cc1ccccc1O)=O Chemical compound CCCCCCCCNC(Cc1ccccc1O)=O BLNSOWYVRUSCDI-UHFFFAOYSA-N 0.000 description 1
- OOPWEZIGEHKNMC-UHFFFAOYSA-N CCCCCCNC(Cc(cc(cc1)O)c1O)=O Chemical compound CCCCCCNC(Cc(cc(cc1)O)c1O)=O OOPWEZIGEHKNMC-UHFFFAOYSA-N 0.000 description 1
- ZOMOCYQAJKJKCL-UHFFFAOYSA-N CCCCCCNC(Cc1ccccc1O)=O Chemical compound CCCCCCNC(Cc1ccccc1O)=O ZOMOCYQAJKJKCL-UHFFFAOYSA-N 0.000 description 1
- BRHVSECCHAIKSL-UHFFFAOYSA-N CCCCCCNC(NCc(cc1)cc(O)c1O)=O Chemical compound CCCCCCNC(NCc(cc1)cc(O)c1O)=O BRHVSECCHAIKSL-UHFFFAOYSA-N 0.000 description 1
- LRVPFWHSEBGDGT-UHFFFAOYSA-N CCCCCCNC(NCc(cc1)ccc1O)=S Chemical compound CCCCCCNC(NCc(cc1)ccc1O)=S LRVPFWHSEBGDGT-UHFFFAOYSA-N 0.000 description 1
- OWCYVWVAZUOMEI-UHFFFAOYSA-N CCCCCCNC(NCc(cc1O)ccc1OC)=S Chemical compound CCCCCCNC(NCc(cc1O)ccc1OC)=S OWCYVWVAZUOMEI-UHFFFAOYSA-N 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000034874 Product colour issue Diseases 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001857 fluorescence decay curve Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012396 frozen pizza Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006195 pent-4-inyl group Chemical group [H]C#CC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical class OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention generally relates to novel compounds, including capsaicin analogues and derivatives thereof, which have anti-oxidative activity, and to their use in medicine, health care, cosmetics and food.
- Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the main component in plants of the Capsicum genus, which include chili peppers, red peppers and paprika.
- Capsaicin comprises a class of compounds that have a lipophilic alkyl chain that is connected, via an amide linkage, to a vanillyl group with a polar hydroxyl group.
- Capsaicin exhibits anti-oxidative activity and can thus act as an anti-oxidant .
- Anti-oxidants are substances that slow or prevent the oxidative process caused by unstable oxidant (or oxidizing) molecules, such as free radicals or reactive oxygen species.
- the biological state in which the production of such oxidant molecules by bodily- systems or external sources overwhelms the natural anti-oxidative capacity is known as 'oxidative stress' .
- Oxidative stress can lead to cellular and tissue damage, and has been implicated as a contributory factor in many diseases and age-related disorders, for example, heart disease, macular degeneration, diabetes, cancer, and inflammatory disorders.
- oxidative processes can lead to deterioration in the quality of products such as food, cosmetics and personal care products.
- the oxidative processes can cause the development of rancidity and odour as well as discolouration of these products.
- Commercial production of capsaicin currently involves isolation of the compound from the plant raw material. Hence, commercial production of capsaicin is currently dependent on the quality, quantity and price of the crop. As capsaicin is only present in the plant in small quantities, isolation of the compound from the plant raw material is difficult and costly.
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluene
- anti-oxidative agents such as novel capsaicin analogues and derivatives thereof, that exhibit potent anti-oxidative properties and reduced or no cytotoxic effects, and that can be easily produced in large quantities at low cost.
- n is an integer from 1 to 5;
- p is an integer from 0 to 4 ;
- Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group;
- R 2 and R 3 are independently a methylene group or a nucleophile, with the proviso that at least one of R 2 and R 3 is a nucleophile group;
- Z is an oxygen (O) atom or sulfur (S) atom
- a pharmaceutical or cosmetic composition comprising as an active ingredient a compound of formula (I) as defined herein and a pharmaceutically or cosmetically acceptable carrier.
- a food preparation comprising a compound of formula (I) as defined herein.
- a compound of formula (I) as defined herein for use in the prevention and/or treatment of a condition associated with oxidative stress and/or a condition caused by presence of free radicals.
- a compound of formula (I) as defined herein in the manufacture of a medicament for the prevention and/or treatment of a condition associated with oxidative stress and/or a condition caused by presence of free radicals.
- a method of preventing and/or treating a condition in a subject comprising administering to the subject an effective amount of a compound of Formula (I) as defined herein, or a pharmaceutically-acceptable salt thereof .
- analogue refers to a compound which comprises a chemically modified form of a specific compound or- class thereof, and which maintains the chemical and/or biological activities that are characteristic of the specific compound and class.
- analogue as used herein may be used to refer to a chemically modified form of a compound of formula (I) which maintains the anti-oxidant properties of a compound of formula (I) .
- derivative refers to any salt, solvate or prodrug, e.g. ester, of a compound of the invention, which upon administration to a subject, is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Preparation of such derivatives is routine to those skilled in the art without undue experimentation.
- active compound in connection with the present invention is understood as meaning a compound as disclosed herein which is capable of causing a required therapeutic or cosmetic effect in a patient or subject, for example an anti-oxidant effect.
- pharmaceutically acceptable salt and “cosmetically acceptable salt” refer to those salts which retain the chemical and/or biological effectiveness and properties of the active compound, which are not otherwise undesirable.
- pharmaceutically and cosmetically acceptable salts are available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991) .
- optionally substituted means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from hydrogen, oxygen, sulfur, alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, carboxyl, haloalkyl, haloalkynyl, hydroxyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulf
- hydroxyl refers to the functional group -OH.
- alkoxy refers to straight chain or branched alkyloxy groups. Examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, and the like.
- thiol means -SH.
- thioether refers to ether groups wherein the oxygen is replaced with a sulfur.
- the thioether groups include but are not limited to -alkylene-S-alkyl, -alkylene-S-aryl, -alkylene-S-arylalkyl, -alkylene-S- alkylaryl, -aryl-S-alkyl , -aryl-S-aryl , -aryl-S- alkylaryl, -aryl-S-arylalkyl, -arylalkyl-S-alkyl, arylalkyl-S-aryl, -arylalkyl-S-alkylaryl, -arylalkyl-S- arylalkyl, -alkylaryl-S-alkyl, -alkylaryl-S-aryl, alkylaryl-S-alkylaryl, and -alkylaryl-S-arylalkyl .
- the thioether groups may
- nucleophile refers to a chemical moiety that has a reactive pair of electrons and that participates in a chemical reaction by donating electrons, i.e., nucleophiles are electron donor compounds.
- the nucleophile may be a halogen, nitrogen, sulfur or oxygen nucleophile.
- Exemplary nucleophiles include fluorides, cyanides, iodides, chlorides, bromides, acetates, enolates, primary amines, secondary amines, amino, alkoxides, thiols, alkyl sulfides (such as mercaptans) , hydroxides, azides, and hydrazines, among others .
- amino refers to groups of the form -NR 3 or -NR 3 Rb wherein R 3 and R b are independently selected from the group including but not limited to hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy and optionally substituted aryl groups.
- amino as used herein may be used to refer to an -NH group at the R 2 and/or R 3 position of a compound of formula (I) , or to an -NHCH 3 group in the optionally substituted aliphatic group at the T position of a compound of formula (I).
- aliphatic refers to a linear, branched, or cyclic alkyl, alkenyl, or alkynyl group.
- alkyl includes within its meaning straight chain or branched chain saturated aliphatic groups having from 1 to 10 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
- alkyl includes, but is not limited to, methyl, ethyl, 1-propyl, isopropyl, 1-butyl, 2-butyl, isobutyl, tert-butyl, amyl, 1, 2-dimethylpropyl, 1, 1-dimethylpropyl, pentyl, isopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 2, 2-dimethylbutyl, 3,3- dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 1, 2, 2-trimethylpropyl, 1, 1, 2-trimethylpropyl, 2- ethylpentyl, 3-ethylpent
- lower alkyl refers to a straight or branched saturated hydrocarbon chain having 1, 2, 3, 4, 5, or 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
- alkenyl includes within its meaning straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms and having at least one double bond, of either E, Z, cis or trans stereochemistry where applicable, anywhere in the alkyl chain.
- alkenyl groups include but are not limited to ethenyl, vinyl, allyl, 1-methylvinyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl, 3-butentyl, 1,3- butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4- pentenyl, 1, 3-pentadienyl, 2, 4-pentadienyl, 1,4- pentadienyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 1, 3-hexadienyl, 1, 4-hexadienyl, 2- methylpentenyl, 1-heptenyl, 2-heptentyl, 3-heptenyl, 1- octenyl, 1-nonenyl, 1-decenyl, and the like.
- lower alkenyl refers to a straight or branched saturated hydrocarbon chain having 2, 3, 4, 5, or 6 carbon atoms.
- alkynyl as used herein includes within its meaning straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms and having at least one triple bond anywhere in the carbon chain.
- alkynyl groups include but are not limited to ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, l-methyl-2-butynyl, 3-methyl-l-butynyl, 1-pentynyl, 1- hexynyl, 1-methylpentynyl, 1-heptynyl, 2-heptynyl, 1- octynyl, 2-octynyl, 1-nonyl, 1-decynyl, and the like.
- the term "lower alkynyl” refers to a straight or branched saturated hydrocarbon chain having 2, 3, 4, 5, or 6 carbon atoms.
- heteroatom or variants such as “hetero-” as used herein refers to oxygen (0) , nitrogen (N) , phosphorus (P) and sulfur (S) .
- aryl or variants such as “aromatic group” or - “arylene” as used herein refers to single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms.
- exemplary aryl groups include, but are not limited to phenyl, naphthyl, tetrahydronaphthyl, and the like.
- heteroaryl and variants such as “heteroaromatic group” or “heteroarylene” as used herein, includes within its meaning single, polynuclear, conjugated and fused aromatic moieties having 5 to 20 atoms wherein 1 to 6 atoms are heteroatoms selected from 0, N, NH and S.
- heteroatoms selected from 0, N, NH and S.
- examples of such groups include pyridyl, 2, 2' -bipyridyl, phenanthrolinyl, quinolinyl, thiophenyl, indoyl, furanyl and pyrrolyl moieties and the like.
- cycloalkyl refers to cyclic saturated aliphatic groups and includes within its meaning monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon moieties having from 3 to 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
- Examples of cycloalkyl groups include but are not limited to cyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, 2-methylcyclopentyl, 3-methylcyclopentyl, cyclohexyl, and the like.
- halide or variants such as “halogen” or “halo” as used herein refers to fluoride, chloride, bromide and iodide.
- the present invention includes within its scope all isomeric forms of the compounds disclosed herein, including all diastereomeric isomers, racemates and enantiomers.
- compounds of formula (I) and derivatives thereof should be understood to include, for example, E, Z, cis, trans, (R) , (S) , (L) , (D) , (+) , and/or (-) forms of the compounds, as appropriate in each case.
- oxidative stress refers to damage to biological molecules resulting from oxidation including, but not limited to, oxidation of lipoproteins and membrane phospholipids; lipid peroxidation; protein damage, including cleavage of amino acid bonds and oxidation of functional groups; nucleic acid strand breaks; nucleic acid base modifications leading to point mutations; inhibition of RNA and protein synthesis; protein cross-linking; impaired maintenance of membrane ion gradients; and depletion of cellular levels of ATP, any of which may lead to cellular dysfunction and eventually to disease.
- anti-oxidative agent refers to a compound having reducing or reductive activity or power, which may prevent the generation of oxidizing molecules such as free radicals and reactive oxygen species, and remove or inactivate such oxidizing molecules, thus preventing, delaying or minimizing oxidative stress, and the damage and deterioration resulting therefrom.
- anti-oxidative agents remove or inactivate the oxidizing molecules by means of electron transfer from the anti-oxidative agent to the oxidizing molecule.
- Anti-oxidative agents disclosed herein have applications in the treatment of one or more oxidative stress related disorder as described below, and in prevention of deterioration in product quality (such as in food, cosmetic and personal care products) . Deterioration in product quality may be for example, development of rancidity and undesirable colour and odour.
- treatment includes any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever. Hence, “treatment” includes prophylactic and therapeutic treatment.
- patient refers to patients or subjects of human or other mammal and includes any individual it is desired to examine or treat using the active compounds and methods disclosed herein. However, it will be understood that “patient” or “subject” does not imply that symptoms are present.
- Suitable mammals that fall within the scope of the invention include, but are not restricted to, primates, livestock animals (eg. sheep, cows, horses, donkeys, pigs) , laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g. cats, dogs) and captive wild animals (e.g. foxes, deer, dingoes).
- “Mammal” refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, and pet companion animals such as a household pet and other domesticated animal such as, but not limited to, cattle, sheep, ferrets, swine, horses, poultry, rabbits, goats, dogs, cats and the like. Preferred companion animals are dogs and cats. Preferably, the mammal is human.
- the term “administering” and variations of that term including “administer” and “administration”, includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, or a surface by any appropriate means.
- an anti-oxidative agent refers to an amount sufficient to effect the desired anti-oxidative benefit.
- therapeutically effective amount refers to an amount sufficient but non-toxic amount of a compound or composition of the invention to provide the desired therapeutic or cosmetic effect.
- pharmaceutically effective amount include within their meanings a sufficient but non-toxic amount of a compound or composition of the invention to provide the desired therapeutic or cosmetic effect.
- the exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "effective amount”. However, for any given case, an appropriate “effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
- dosage unit form refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a predetermined quantity of compound (s) is calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the compound (s) may be formulated for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit.
- the dosages are determined by reference to the usual dose and manner of administration of the ingredients.
- the term "about”, in the context of concentrations of components of the formulations, typically means +/- 5% of the stated value, more typically +/- 4% of the stated value, more typically +/- 3% of the stated value, more typically, +/- 2% of the stated value, even more typically +/- 1% of the stated value, and even more typically +/- 0.5% of the stated value.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- the active compounds disclosed herein exhibit potent anti-oxidative activity with reduced or no cytotoxicity. Accordingly, the active compounds disclosed herein can be used as anti-oxidative agents in medicaments and health supplements to treat and/or prevent diseases or conditions associated with oxidative stress and/or caused by presence of free radicals, and in cosmetic products to produce an anti- oxidative effect for example an anti-aging effect.
- the active compounds disclosed herein can also be used as anti-oxidative agents to stabilize food, cosmetic and personal care products against deterioration.
- the Active Compounds may be represented by compound having the general formula (I) :
- Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group;
- R 2 and R 3 are independently a methylene group or a nucleophile, with the proviso that at least one of R 2 and R 3 is a nucleophile group;
- n can be 1, 2, 3, 4 or 5.
- Z is an oxygen (0) atom.
- Z is not a sulfur (S) atom.
- the compounds of formula (I) exhibit high anti-oxidant activity and reduced or no cytotoxicity.
- n is between 1 to 3.
- n is 2. In one embodiment where n is 2, Ri is on the carbon-3 position and the carbon-4 position of the phenyl group. In another embodiment where n is 2, Ri is on the carbon-2 position and the carbon-5 position of the phenyl group.
- each of Ri is -OH.
- one of Ri is on the carbon-3 position and the other Ri is on the carbon-4 position of the phenyl group.
- Z is an oxygen (0) atom
- n is 2
- each of Ri is -OH.
- Z is not a sulfur (S) atom
- n is 2, and each of Ri is -OH.
- n is 1 and Ri is on the carbon-4 position of the phenyl group.
- Ri is on the carbon-2 position of the phenyl group.
- p can be 0, 1, 2, 3 or 4.
- p is 1.
- Ri is OU wherein U is an alkyl group having from 1 to 6 carbon atoms.
- Ri is ZiTi, wherein Zi is a sulfur (S) atom or oxygen (O) atom and Ti is a lower alkyl group.
- the lower alkyl may have from 1 to 6 carbon atoms .
- Ri is independently selected from the group consisting of -OH, -OCH 3 , OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH 2 CH 2 CH 2 CH 3 , -OCH 2 CH 2 CH 2 CH 3 , - OCH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -SH, -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH 2 CH 2 CH 2 CH 3 , -SCH 2 CH 2 CH 2 CH 3 and -SCH 2 CH 2 CH 2 CH 2 CH 2 CH 3 .
- n 2, 3, 4 or 5, all the Ri groups are the same.
- both Ri groups may be -OH, both Ri groups may be -OCH 3 , both Ri groups may be OCH 2 CH 3 , both R 1 groups may be -OCH 2 CH 2 CH 3 , both Ri groups may be -OCH 2 CH 2 CH 2 CH 3 , both Ri groups may be -OCH 2 CH 2 CH 2 CH 3 , both Ri groups may be OCH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , both R 1 groups may be -SH, both Ri groups may be -SCH 3 , both Ri groups may be -SCH 2 CH 3 , both Ri groups may be -SCH 2 CH 2 CH 3 , both Ri groups may be -SCH 2 CH 2 CH 3 , both Ri groups may be -SCH 2 CH 2 CH 2 CH 3 , both Ri groups may be -SCH 2 CH 2 CH 2 CH 3 , both Ri groups may be -SCH 2 CH 2 CH 2 CH 3 , both Ri groups may be -SCH 2 CH 2 CH 2 CH 3
- each Ri group is different.
- one Ri group may be -OH and the other Ri group may be OCH2CH2CH3, or where n is 3, two Ri groups may be -OH and the third R 1 group may be -OCH 3 or the first Ri group may be -OH, the second R 1 group may be -OCH 3 and the third Ri group may be -OCH 2 CH 2 CH 3 .
- n is 2 and one of Ri is -OH and the other of Ri is -OCH 3 .
- T is an aliphatic group with 1 to 20 carbons. In a preferred embodiment, T is an aliphatic group with 1 to 10 carbons. In a more preferred embodiment, T is an aliphatic group with 5 to 10 carbons.
- the aliphatic group of T is an alkyl, preferably a lower alkyl.
- the alkyl may be straight chain alkyl or a branched chain alkyl.
- the alkyl is a straight chain alkyl.
- the alkyl may be -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 or CH(CH 3 ) 2 .
- the aliphatic group of T is an aliphatic group containing at least one unsaturated alkenyl or alkynyl group, preferably lower alkenyl or lower alkynyl groups.
- Suitable alkenyl groups include - CHCH 2 , -CH 2 CHCH 2 , -CHCHCH 3 , and -CHCHCH 3
- suitable alkynyl groups include -CCCH 3 , -CH 2 CCH, -CH 2 CH 2 CCH, CH 2 CH 2 CH 2 CCH, -CH 2 CH 2 CH 2 CH 2 CCH, and -CH 2 CCCH 3 .
- T is an aliphatic group substituted with one or more heteroatom groups. Suitable heteroatom groups include, without limitation, oxygen (0), sulfur (S), and nitrogen (N) and phosphorous (P).
- T is an aryl group, heteroaryl group or cycloalkyl group, each optionally substituted with one or more groups selected from hydrogen, oxygen, sulfur, alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, carboxyl, haloalkyl, haloalkynyl, hydroxyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine,
- both R 2 and R 3 are methylene groups. In another embodiment, one of R 2 and R 3 is a methylene group and the other is a nucleophile. In yet another embodiment, both R 2 and R 3 are nucleophiles .
- the nucleophile of R2 and/or R 3 is selected from the group consisting of a halide, a nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile .
- Suitable halides include, but are not limited to, fluoride, chloride, bromide and iodide, and the like.
- Suitable nitrogen nucleophiles include, but are not limited to, amino groups (e.g. primary amino groups, secondary amino groups and tertiary amino groups) , and azides (e.g. metal azides of Li, Na or K), and the like.
- Suitable sulfur nucleophiles include thiols and alkyl sulfides, and the like.
- Suitable oxygen nucleophiles include acetates, enolates, alkoxides, and hydroxides, and the like.
- halide, nitrogen nucleophile, sulfur nucleophile and oxygen nucleophile may be optionally substituted as described above.
- the nucleophile of R 2 and/or R 3 is a nitrogen nucleophile.
- the nitrogen nucleophile is an amino group.
- the amino group may be a NH group, a NHV group or a NW group where V and V are each independently selected from the group consisting of a Ci-
- the compound has the formula (II):
- the compound has the formula (III) :
- the compound has the formula
- the compound has the formula (V)
- the compound has the formula
- the compound has the formula (VII) :
- the compound has the formula (VIII):
- the compound has the formula
- the compound has the formula (X)
- the compound has the formula
- the compound has the formula
- the compound has the formula (XIII) :
- the compound has the formula (XIV) :
- the compound has the formula (XV) :
- the compound has the formula
- the compound has the formula
- the compound has the formula
- the disclosed active compounds may have asymmetric carbon centers, they can be present in the form of racemate, diastereomers or mixtures thereof. Therefore, the present invention also includes all these isomers and their mixtures.
- the disclosed active compounds having the general formula (I) may be prepared by a process as described below.
- the active compounds are synthesized via nucleophilic substitution reactions.
- a nucleophile and a second reactant (an electrophile) are mixed in an anhydrous solvent, and stirred at room temperature to produce the active compounds.
- the active compounds are extracted with an organic solvent, and the resulting organic extracts are concentrated under reduced pressure to give a crude product.
- the nucleophile is an amine having a formula (Ia) , or a hydrochloride or hydrobromide salt thereof having a formula (Ia') as shown below:
- nucleophile is a straight chain amine having a formula (Ia"):
- the electrophile is an acid chloride (such as a nonanoyl chloride) , an isocyanate or isothiocyanate, or a lactone .
- nucleophile and the electrophile are typically used in a stoichiometric ratio, but the excess of one component or the other may be advantageous.
- the anhydrous solvent is N, N-dimethylformamide (DMF) , dichloromethane or tetrahydrofuran.
- the nucleophile used is a hydrochloride or hydrobromide salt of an amine having a formula (Ia' )
- DIPEA N,N-diisopropylethylamine
- the electrophile used is a lactone, 2- hydroxypyridine is added as a reaction catalyst.
- the mixture is stirred at room temperature for 6 to 24 h before being extracted with an organic solvent such as dichloromethane.
- the organic extract is concentrated under reduced pressure to give a crude active compound, which is then purified using silica gel column chromatography or preparative high performance liquid chromatography.
- the active compounds in pharmaceutically or cosmetically acceptable salt form, generally to improve the solubility and bioavailability and to provide an active compound that may be capable of being assimilated readily.
- the pharmaceutically or cosmetically acceptable salts are suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- the active compounds may form pharmaceutically or cosmetically acceptable salts with both organic and inorganic acids.
- Suitable physiologically tolerated acids for salt formation may be organic and inorganic acids, such as hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic, isethionic, lactic, gluconic, glucuronic, sulfamic, benzoic, tartaric, pamoic, and the like.
- the salts may be prepared by contacting a free base form with an equivalent amount of the desired acid in the conventional manner.
- the free base forms may be regenerated by treating the salt form with a base.
- dilute aqueous base solutions may be utilized.
- Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions may be suitable for this purpose.
- the free base forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvent. Otherwise, the salts may be equivalent to their respective free base forms for purposes of the invention.
- the active compounds may exist in unsolvated as well as solvated forms, including hydrated forms. Such salt forms of the active compound may be provided or mixed prior to use with a physiologically acceptable solvent such as water or ethanol.
- the active compounds of general formula (I) have potent anti-oxidant activity, and reduced or no cytotoxicity.
- the disclosed active compounds may be capable of stopping or preventing oxidative stress in a subject.
- the disclosed active compounds may be envisaged as being useful for use as anti-oxidative agents in the treatment, prevention, inhibition or amelioration of one or more oxidative stress related disorders or condition, and/or conditions caused by presence of free radicals in a subject.
- Subjects having or at risk of developing an oxidative stress related disorder include those having inflammatory disorders, autoimmune disorders such as rheumatoid arthritis, lupus and neurodegenerative disease such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS) , atherosclerosis, cerebral ischemia, hepatopathy, diabetes, nervous diseases, renal diseases, hepatic cirrhosis, arthritis, retinopathy of prematurity, ocular uveitis, retinal rust disease, senile cataract, asbestos diseases, bronchial failures due to smoking, cerebral edema, pulmonary edema, foot edema, cerebral infarction, coronary artery disease, hemolytic anemia, progeria, epilepsy, Crohn's disease, Kawasaki disease, collagen disease, progressive systemic sclerosis, herpetic dermatitis, immune deficiency syndrome or the like.
- ALS amyotrophic lateral sclerosis
- the active compounds may be provided as a pharmaceutical composition in the form of a medicament as discussed below.
- Another aspect of using the active compounds as anti-oxidative agents is on the preventive side. Instead of waiting for the free radicals to make a long chain of free radicals and cause oxidative damage to cells and tissues, the active compounds scavenge and destroy the initiating free radicals before oxidation is set in motion, to thereby delay the onset and progress of the aging process and prevent onset of an oxidative stress related disease.
- the active compounds disclosed herein may be provided in pure form or with one or more other ingredients in a health supplement.
- the active compounds may be provided in pure form or with one or more other ingredients in a cosmetic formulation as discussed below.
- the active compounds for use as an anti-oxidative agent may be administered in pure form or in an appropriate pharmaceutical composition.
- suitable pharmaceutical compositions may be prepared according to methods which are known to those of ordinary skill in the art.
- the compositions comprising the active compounds disclosed herein may include a conventional pharmaceutical carrier or diluent, and in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.
- suitable pharmaceutical carriers or diluents include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
- suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences (Mack Publishing Company) , a standard reference text in this field, or in U.S. Pharmacopeia National Formulary, 1857-1853, (1990).
- the carrier(s) or diluent (s) will form from about 10% to about 99.9% by weight of the compositions.
- Administration of the active compounds disclosed herein, in pure form or in an appropriate pharmaceutical composition may be carried out via any of the acceptable modes of administration or pharmaceutically acceptable means of delivery.
- the modes of administration and pharmaceutically acceptable means of delivery may include oral administration or delivery in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms.
- the dosage forms may include tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
- Oral administration of the disclosed active compounds may be effected by preparing a mixture of the disclosed active compounds with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- the disclosed active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations may contain the active compounds in an amount by weight percent selected from the group consisting of about 0.1% to about 70%, about 0.5% to about 65%, about 1% to about 60%, about 2% to about 55% and about 3% to about 50%.
- the tablets, troches, pills, capsules and the like may also contain the following: a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring may be added.
- a binder such as gum tragacanth, acacia, cornstarch, or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin or a flavoring
- the active compounds disclosed herein may be administered parenterally or intraperitoneally .
- Solutions of the disclosed active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose .
- Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use may include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the pharmaceutical form may further include a suitable buffer to minimise acid hydrolysis.
- Suitable buffer agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.
- the active compounds may also be administered in the form of a "prodrug".
- a prodrug is an inactive form of a compound which is transformed in vivo to the active form.
- Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.
- the active compounds in pharmaceutically acceptable form may be administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compounds employed; the metabolic stability and length of action of the compounds; the age, body weight, general health, sex and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disease states; and the patient undergoing treatment.
- Single or multiple administrations of the pharmaceutical compositions according to the invention may be carried out.
- One skilled in the art would be able, by routine experimentation, to determine effective, non- toxic dosage levels of the compound and/or composition of the invention and an administration regime which would be suitable for treating the diseases and/or conditions to which the compounds and compositions are applicable.
- an effective dosage per 24 hours for use of the active compounds as anti-oxidative agents in a pharmaceutical composition may be in the range of about 0.5 mg per kg body weight to about 10 mg per kg body weight; suitably, about 1 mg per kg body weight to about 6 mg per kg body weight.
- an effective dosage may be up to about 20 mg per kg body weight.
- an effective dosage is expected to be in the range of about 10 to about 20 mg per kg body weight .
- the active compounds of the invention may be used in combination with other known treatments or anti-oxidative agents. Combinations of active agents, including the active compounds of the invention, may be synergistic.
- the active compounds disclosed herein may also be used to provide anti-oxidative effect in the form of cosmetic formulations such as anti-aging creams, lipstick, face cream, body lotion, moisture creams, burn remedies containing local anesthetics and the like.
- the active compounds have protective effect against damage to the skin that is induced by UV light, and hence prevent damage caused by radiation from natural or artificial sources such as the sun, either alone or in combination with sunscreen agents such as PABA.
- the active compounds may be used individually or in combination with one or more other ingredients in the cosmetic formulation, such as solvents, emollients, humectants, emulsifiers, surfactants, thickeners, coloring agents, preservatives (such as anti-bacterial agents, anti-viral agents, anti-fungal agents) , vitamins, antibiotics, anti-inflammatory agents, anti-acne agents, anti-irritants, anti-dandruff agents, anti-perspirants, anti-wrinkle agents, whitening agents, moisturizing agents, and fragrances, among others.
- Cosmetically acceptable ingredients and formulations are also discussed in, for example, FDA Cosmetics Handbook, U.S.
- the active compounds are "cosmetically acceptable” in terms of being compatible with the other ingredients of the cosmetic formulation, and not deleterious to the recipient thereof.
- the cosmetic formulations to which the active compounds may be added are preferably in a form suitable for topical administration, although cosmetic preparations in a form suitable for administration by parenteral injection (such as subcutaneous, intramuscular or intravenous injection), oral ingestion (such as capsules, tablets, caplets and elixirs) , or inhalation
- Topical formulations preferably hypoallergenic and pH-controlled, include liquid or semi- liquid preparations such as lotions or liniments, creams, ointments or pastes, drops, tinctures, salves, patches, powders and solutions containing the active compounds disclosed herein and one or more cosmetically acceptable carriers, and optionally any other ingredients as discussed above.
- compositions comprising the active compounds disclosed herein and other ingredients described above are apparent to those skilled in the art, and are described in, for example, Remington 's Pharmaceutical Science, 15th ed. , Mack Publishing Company, Easton, Pa.
- the dosage, frequency and duration of administration of a cosmetic formulation comprising the disclosed active compounds is dependent on factors including the nature of the formulation (for example, its concentration, the presence or lack of other active ingredients, and the delivery system used) , the severity and extent of the condition being treated, the form, route and site of administration, the discretion of the individual being treated, and in some cases, the judgment of a skin care professional (for example, a dermatologist or a cosmetologist).
- the dosage, frequency and duration required to achieve a cosmetic effect can be readily determined by one of ordinary skill in the art. Typical effective dosages are expected to be in the range of about 0.01 ⁇ g/mL to about 2 mg/mL.
- the active compounds are used in an amount of about 0.01 ⁇ g/mL to about 1.5 mg/mL, about 0.01 ⁇ g/mL to about 1 mg/mL, about 0.01 ⁇ g/mL to about 100 ⁇ g/mL, about 0.01 ⁇ g/mL to about 10 ⁇ g/mL, about 0.01 ⁇ g/mL to about 1 ⁇ g/mL, about 0.1 ⁇ g/mL to about 2 mg/mL, about 1 ⁇ g/mL to about 2 mg/mL, about 10 ⁇ g/mL to about 2 mg/mL, about 100 ⁇ g/mL to about 2 mg/mL, about 1 mg/mL to about 2 mg/mL or about 1.5 mg/mL to about 2 mg/mL.
- Typical frequencies of administration are expected to be about once, twice, three times, four times, five times, or six times per week, or about once, twice, three times, four times, five times, or six times per day. In some embodiments, the administration is carried out about once to about three times per day. In some embodiments, the administration is carried out about twice to about four times per day. In some embodiments, the administration is carried out more than about three times per day. Where administration is carried out twice per day, the administration is typically in the morning and in the evening.
- ⁇ V food and "food product” as used herein refers to any edible substance for human consumption as well as feed for animal consumption (e.g. pet food, animal feed).
- edible substances suitable for human or animal consumption that may be stabilized against oxidation using the active compounds disclosed herein include, but are not limited to, frying oils and fats such as tallow, lard, peanut oil, corn oil, cottonseed oil, olive oil, safflower oil, soybean oil, coconut oil, shortening, cooking oils, salad oils and dressings; potato flakes; bakery products; meat emulsions; precooked cereals; instant noodles; soybean milk; chicken products; emulsion products such as sausage; mayonnaise and margarine; frozen fish; frozen pizza; cheese and animal foods.
- the oils and fats may be naturally-occurring, such as animal or vegetable fats, or synthetic materials.
- the active compounds disclosed herein may be used in an amount based on the weight of the edible substance, which amount is effective as an anti-oxidant , that is an amount sufficient to stabilize, or retard the deterioration of, the edible substances to be stored and used to prepare foods in a normal and acceptable manner.
- the amount of the active compound employed is any amount which may have a significant stabilizing effect, and may depend on various factors, such as the desired period of stability of the edible substance, the rate of deterioration of the edible substance, the type of oxidation to be stabilized against, and the type of edible substance etc. For example, when a prolonged storage life of the edible substance before use is desired, increased amounts of the active compounds may be used.
- the active compounds are used in an amount of about 0.001% to about 5%, of about 0.005% to about 5%, of about 0.01% to about 5%, of about 0.05% to about 5%, of about 0.1% to about 5%, of about 0.5% to about 5%, of about 1% to about 5%, of about 2% to about 5%, of about 3% to about 5%, of about 4% to about 5%%, of about 0.001% to about 4%, of about 0.001% to about 3%, of about 0.001% to about 2%, or of about 0.001% to about 1%, by weight based on the weight of the edible substance.
- the active compounds disclosed herein may be used in pure form or in combination with one or more other antioxidants to achieve desirable combinations of properties of stability.
- the active compounds disclosed herein may be used in combination with one or more of the phenolics (e.g. BHA and BHT); tocopherols
- benzylphosphonates e.g. dimethyl-2, 5-di-tert-butyl-4-hydroxybenzylphos- phonate and diethyl-3, 5-di-tert-butyl-4-hydroxy- benzylphosphonate
- ascorbic acid (vitamin C) phosphites and phosphonites (e.g.
- the active compounds may also be used in combination with one or more other food additives such as emulsifiers (e.g.
- mono- and di-glycerides of saturated or unsaturated fatty acids such as monoglyceryl palmitate, polyoxyethylene derivatives of hexahydric alcohols such as sorbitol, glycols, glycol esters, polyglycerol esters, sorbitan esters, stearoyl lactylate, acetic acid esters, lactic acid esters, citric acid esters, acetylated monoglyceride, diacetyl tartaric acid esters, polyoxyethylene sorbitan esters such as polysorbate 80, sucrose esters, lecithin, egg yolk, and mixtures thereof) , suspension agents and colorings to provide the desired qualities in the final food product.
- polyoxyethylene sorbitan esters such as polysorbate 80, sucrose esters, lecithin, egg yolk, and mixtures thereof
- the presence of the active compounds disclosed herein does not materially affect the manner in which the edible substance is formulated or in which it is used to prepare food or food products.
- the active compounds may be added at the time of food preparation or may be premixed with the edible fat or fatty oils to stabilize them prior to food preparation.
- the active compounds are uniformly admixed in the edible substance.
- the active compounds disclosed herein are suitable for use in both small-scale and large-scale production of food and food products. (B) Use as Stabilizers in Cosmetic and Personal Care Products
- Cosmetic and personal care products that may be stabilized by the active compounds include those that may be applied to any part of the human body, such as skin, hair or nails.
- Exemplary cosmetic and personal care products include, but are not limited to, lipsticks and other lip care products, make-up, foundations, facial masks, detergents, hair colorants, liquid soaps, bar soaps, creams, lotions, bath gels, hand cleaners, facial cleansers, exfoliants, sunscreens, conditioners, shampoos, shaving creams, hair detanglers, hot oil treatments, toilet waters, and fabric softeners, and the like.
- the amount of the active compound employed is any amount which may have a significant stabilizing effect, and may depend on various factors, such as the desired period of stability of the cosmetic o ' r personal care product, the rate of deterioration of the cosmetic or personal care product, the type of oxidation to be stabilized against, and the type of the cosmetic or personal care product.
- the active compounds are used in an amount of about 0.001% to about 5%, of about 0.005% to about 5%, of about 0.01% to about 5%, of about 0.05% to about 5%, of about 0.1% to about 5%, of about 0.5% to about 5%, of about 1% to about 5%, of about 2% to about 5%, of about 3% to about 5%, of about 4% to about 5%%, of about 0.001% to about 4%, of about 0.001% to about 3%, of about 0.001% to about 2%, or of about 0.001% to about 1%, by weight based on the weight of the cosmetic or personal care product.
- the active compounds may be used in pure form or in combination with one or more other ingredients in the cosmetic and personal care product, such as solvents, emollients, humectants, emulsifiers, surfactants, thickeners, coloring agents, preservatives (such as antibacterial agents, anti-viral agents, anti-fungal agents), vitamins, antibiotics, anti-inflammatory agents, antiacne agents, anti-irritants, anti-dandruff agents, anti- perspirants, anti-wrinkle agents, whitening agents, moisturizing agents, and fragrances, among others.
- suitable ingredients and formulations are also discussed in, for example, FDA Cosmetics Handbook, U.S.
- Fig. 1 shows the dose response curve of analogue JC017 in cytotoxicity assays using A549 and HepG2 cell lines .
- Fig. 2 shows the dose response curve of analogue JC058 in cytotoxicity assays using A549 and HepG2 cell lines.
- Fig. 3 shows a comparison of the cytotoxicity of analogues JC017 and JC058 in a cytotoxicity assay using the A549 cell line.
- Fig. 4 shows a comparison of the cytotoxicity of analogues JC017 and JC058 in a cytotoxicity assay using the HepG2 cell line.
- Non-limiting embodiments of the disclosed active compounds will be further described in greater detail by reference to specific Examples, which should not be construed as in any way limiting the scope of the invention.
- Analytical HPLC was performed on a Waters HPLC system equipped with a Waters 2998 PDA detector, Waters 2695 separation module using a Phenomenex Luna C18(2) (4.6 mm I. D. * 150 mm, 5 ⁇ ) column. A gradient elution starting with 20% CH 3 CN, 80% (0.1% formic acid/H 2 O) , and ending with 100% CH 3 CN at a flow rate of 1.0 mL/min over 15 min was used.
- LC-MS data was collected on a Shimadzu LCMS-IT-TOF instrument equipped with SPD-M20A PDA detector, LCMS-IT- TOF MS detector and LC-20AD binary gradient pump using a Shimpack VP-ODS (2.0 mm I. D. * 150 mm) column.
- An isocratic elution with 20% H 2 O and 80% CH 3 CN at a flow rate of 0.2 mL/min over 3 min was used.
- reaction mixture was transferred to a separating funnel and extracted with dichloromethane, CH2CI2 (3 * 10 mL) .
- the organic extracts were concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (using hexane/ethyl acetate, 2:1 v/v, as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product.
- the suspension containing the precipitated analogues was transferred to a Falcon tube and centrifuged. The supernatant was discarded. The pellet was re-suspended with ethyl acetate
- Example 4 Synthetic Procedure for Analogues JC003, JC009, JC012, JC016 and JC018-JC022
- the suspension containing the precipitated analogues was transferred to a Falcon tube and centrifuged. The supernatant was discarded. The pellet was re-suspended with ethyl acetate (5 mL) and centrifuged. The re-suspension and centrifugation steps were carried out twice.
- the crude product obtained was further purified by preparative HPLC (using the protocol set out in "Analytical Protocols" above) .
- Total anti-oxidant activity can be measured using various assays that are based on different reaction mechanisms. These include the Oxygen Radical Absorbance Capacity (ORAC) assay, the Total Radical Trapping Antioxidant Parameter (TRAP) assay, the Total Equivalent Anti-oxidant Capacity (TEAC) assay, and the 2, 2-Diphenyl- 1-picrylhydrazyl Radical Scavenging Capacity (DPPH) assay.
- ORAC Oxygen Radical Absorbance Capacity
- TRAP Total Radical Trapping Antioxidant Parameter
- TEAC Total Equivalent Anti-oxidant Capacity
- DPPH 2, 2-Diphenyl- 1-picrylhydrazyl Radical Scavenging Capacity
- the DPPH assay is also a simple and accurate method for measuring anti-oxidant levels.
- the DPPH assay was used as a comparison to the ORAC assay for obtaining additional information on the reducing power of the test samples (Mahattanatawee et al., 2006, J. Agric. Food Chem. 54, 7355-7363) .
- AAPH 2,2-Diphenyl-l-picrylhydrazyl
- DPPH 2,2-Diphenyl-l-picrylhydrazyl
- resazurin purchased from Sigma-Aldrich. Fluorescence natrium was purchased from Merck and Trolox was purchased from Acros. All measurements were carried out with Tecan Infinite 200.
- the ORAC assay is based on the free radical damage caused to a fluorescent probe.
- the assay applies a thermal peroxyl radical (R00») generator, the azo compound 2, 2 ' -azobis (2-amidinopropane) dihydrochloride (AAPH) , to give a steady flux of peroxyl radicals in an air-saturated solution.
- the loss of fluorescence intensity of a fluorescein probe is an indication of the extent of the damage resulting from its reaction with the peroxyl radical.
- the protective effect of an anti-oxidant is measured by assessing the area under the fluorescence decay curve (AUC) of the sample as compared to that of the blank in which no anti-oxidant is present (Ou et al., 2001, J. Agric. Food Chem. 49, 4619- 4626).
- the ORAC assay was performed as described by Huang et al (Huang et al., 2002. J. Agric. Food Chem. 50, 4437-4444) with some minor modifications. Firstly, the capsaicin analogues were dissolved in methanol and added in volumes of 10 ⁇ l/well into a black 96-well plate in duplicate or triplicate with serial dilutions. 150 ⁇ l of 80 nM fluorescein was then added to the 96-well plate, followed by the addition of 40 ⁇ l of 100 mM AAPH (2,2'- azobis (2-amidinopropane) dihydrochloride). The plate was read immediately after addition of the AAPH at two minute intervals at an excitation wavelength of 485 nM and an emission wavelength of 535 nM at 37°C for 2 hours.
- the template of a 96-well plate in an ORAC assay is as follows: 10 11 12
- the ORAC values were calculated according to Huang et al. (supra) .
- the net area under the curve (AUC) of the Trolox standard and the test samples were also calculated using the following equation:
- AUC O.5+(R2/R1)+(R3/R1)+(R4/R1)+ + 0.5(Rn/Rl) (Eq. 1) where Rl is the fluorescence reading at the initiation of the reaction and Rn is the final measurement.
- the Net AUC was calculated using the following equation:
- DPPH Assay DPPH is one of a few stable and commercially available organic nitrogen radicals and has an absorption maximum at 517 nm.
- the ability of a compound to scavenge stable [DPPH] * is a widely used method for evaluating Radical-Scavenging Capacity (RSC) in a relatively short time compared to other methods.
- RSC Radical-Scavenging Capacity
- the progress of the reaction is easily monitored by a spectrophotometer (Molyneux, 2004; Eklund et al., 2005; and Shama et al. , 2009) .
- the DPPH assay was modified and carried out with a 9 ⁇ -well plate (Molyneux, 2004; Eklund et al., 2005; Shama et al., 2009).
- a 190 ⁇ l/well DPPH solution (150 ⁇ M) in methanol was mixed with a 10 ⁇ l/well sample dissolved in methanol.
- the progress of the reaction was monitored by determining the absorbance of the mixture at 517 nm after 30 min.
- the template of a 96-well plate in a DPPH assay is as follows:
- the percentage of the " remaining [DPPH]* is proportional to the anti-oxidant concentration, and the concentration that scavenges 50% of the initial [DPPH]* is defined as EC50.
- the cytotoxicity assay was conducted using the HepG2 (human hepatocellular carcinoma, ATCC HB-8065) and A549 (human lung carcinoma, ATCC CCL-185) cell lines.
- the assay is based on the use of an indicator dye resazurin to measure the metabolic capacity of a cell.
- a viable cell would retain the ability to reduce resazurin to resorufin, which is a highly fluorescent compound.
- a non-viable cell would rapidly lose its metabolic capacity, and hence would not reduce the resazurin to generate the fluorescent resorufin signal.
- lOVmL HepG2 or A549 cells 100 ⁇ L of lOVmL HepG2 or A549 cells was added to each well in a 96-well plate. The cells were incubated at 37°C overnight. On the second day, 10 ⁇ L of the test sample was then added to each well and the mixture incubated for 24 h at 37°C. On the third day, 20 ⁇ L of 1.8 mg/mL resazurin were added to each well and the mixture incubated for 4 h at 37°C. The plate was then read at an excitation wavelength of 535 nm and an emission wavelength of 590 nm with a Tecan Infinite 200 microplate reader.
- the template of the 9 ⁇ -well plate used in a cytotoxicity assay was similar to the template used in the DPPH assay, except that 10% DMSO was used as the solvent for the test sample and controls.
- the data was also processed using the same equation as in the DPPH assay (i.e. Eq. 3) .
- Capsaicin analogues with differing levels of anti- oxidant activity were prepared and analyzed as set out in Examples 1-7 above.
- the analogue JC017 demonstrated the most potent anti-oxidant activity.
- the anti-oxidant activity of JC017 was 6.3 ⁇ mol TE/ ⁇ mol in the ORAC assay and the EC50 was 40 ⁇ M in the DPPH.
- the antioxidant activity of capsaicin was about 3.3 ⁇ mol TE / ⁇ mol in the ORAC assay and the EC50 was 69 ⁇ M in the DPPH assay.
- Analogues JC014, JC016, JC018, JC022 and JC026 exhibited similar antioxidant activities to capsaicin in the ORAC assay.
- the activities of these analogues in the ORAC assay ranged from 3.4 ⁇ mol TE / ⁇ mol to 3.9 ⁇ mol TE / ⁇ mol.
- the EC50 of analogues JC014, JC018 and JC026 ranged from 30 ⁇ M to 89 ⁇ M, which is similar to the EC50 of capsaicin.
- analogues JC016 and JC022 did not exhibit any nitrogen radical- scavenging activity in the DPPH assay.
- the analogues JC004, JC005, JC006, JC007, JCOlO, JCOIl, JC012, JC023, JC024 and JC025 showed moderate activity ranging from 1.3 ⁇ mol TE/ ⁇ mol to 2.5 ⁇ mol TE/ ⁇ mol in the ORAC assay.
- JC004, JC005, JC006, JC007, JCOlO, JCOIl and JC025 exhibited activities with EC50 values ranging from 28 ⁇ M to 178 ⁇ M while JC012, JC023 and JC024 did not exhibit any activity in the DPPH assay.
- the analogues JC013, JC015 and JC021 exhibited minor anti-oxidant activity of 0.2 ⁇ mol TE / ⁇ mol, 0.5 ⁇ mol TE / ⁇ mol and 0.6 ⁇ mol TE / ⁇ mol respectively in the ORAC assay. None of these analogues exhibited any activity in the DPPH assay.
- capsaicin analogues tested demonstrated cytotoxicity at concentrations of up to 350 ⁇ M except for analogues JC024, JC025 and JC026, which exhibited slight cytotoxicity in HepG2 cell lines.
- JC024 and JC026 having IC50 values of 304 ⁇ M and 254 ⁇ M respectively, were less cytotoxic when compared to capsaicin, which has an IC50 of 178 ⁇ M in HepG2 cell lines.
- JC025 having an IC50 of 125 ⁇ M was slightly more cytotoxic than capsaicin.
- capsaicin analogues disclosed herein, particularly analogues JC005, JC006, JC007, JCOlO, JCOIl, JC012, JC013, JC014, JC015, JC016, JC017, JC018, JC022, JC023, JC024, JC025 and JC026, were easily obtained through a simple synthetic procedure at a reduced cost compared to the high cost of isolating capsaicin from chili pepper.
- Those capsaicin analogues with no cytotoxicity can be used as potent anti-oxidative agents in medicine, health supplements, cosmetic formulations, and stabilizers in food, cosmetics and personal care products.
- Analogues JC017 and JC058 were synthesized based on the procedure set out in Example 3 above.
- Analogue JC058 has the same structure as analogue JC017 except that the oxygen at the ⁇ Z' position of formula (I) is replaced with a sulfur in JC058.
- the structures of both analogues are shown in Table 3 below.
- the anti-oxidant activities of both analogues JC058 and JC017 were analyzed using the ORAC and DPPH assays as set out above.
- the cytotoxicity of both analogues JC058 and JC017 were also assayed using the HepG2 and A549 cell lines according to the protocol set out above.
- analogue JC017 clearly exhibits significantly lower cytotoxicity than analogue JC058 in both the HepG2 cell line as well as in the A549 cell line.
- substitution of the sulfur atom on the carbonyl group of analogue JC058 with an oxygen atom in analogue JC017 confers the advantage of reducing the cytotoxocity of the compound while maintaining high antioxidant activity.
- Fig. 1 The dose response curves for analogue JC017 in a cytotoxicity assay using the cell lines HepG2 and A549 are shown in Fig. 1 while the dose response curves for analogue JC058 in a cytotoxicity assay using the cell lines HepG2 and A549 are shown in Fig. 2.
- JC017 when analogue JC017 was administered at varying concentrations to the HepG2 cell line, cell inhibition was relatively low, and ranged, on average, from 0% to about 40% after exposing the cell lines to varying concentrations of between 0.02 mM and 1.5 mM analogue JC017 for 24 hours.
- the IC50 of JC017 in the HepG2 cell line was higher than 1.5 mM.
- analogue JC017 is less cytotoxic than analogue JC058.
- analogues JC017 and JC058 both have comparably high anti-oxidant activity.
- Analogue JC017 has the added advantage of having low cytotoxicity.
- the active compounds disclosed herein have demonstrated strong anti-oxidative activity.
- the disclosed active compounds are useful as anti-oxidative agents.
- the disclosed active compounds are useful as anti-oxidative agents in medicines to treat a patient suffering from an oxidative stress related disorder or condition.
- the disclosed active compounds are also useful as anti-oxidative agents in health supplements and cosmetic formulations to prevent and delay aging caused by oxidative stress.
- the disclosed active compounds are furthermore useful as anti-oxidative agents for stabilizing food, cosmetics and personal care products against oxidative damage.
- the disclosed active compounds have very low toxicity to humans and therefore are ideal for use in medicine, particularly for use in medicines for treating patients suffering from oxidative stress related disorders.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to compounds represented by the general formula (I): and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group; R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group; Z is an oxygen (O) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group; with the proviso that when n = 2, R1 is not -OCH3 on the carbon-3 position of the phenyl group and R1 is not -OH on the carbon-4 position of the phenyl group.
Description
NOVEL COMPOUNDS AND USES THEKEOF
Technical Field
The present invention generally relates to novel compounds, including capsaicin analogues and derivatives thereof, which have anti-oxidative activity, and to their use in medicine, health care, cosmetics and food.
Background
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the main component in plants of the Capsicum genus, which include chili peppers, red peppers and paprika. Capsaicin comprises a class of compounds that have a lipophilic alkyl chain that is connected, via an amide linkage, to a vanillyl group with a polar hydroxyl group.
Capsaicin exhibits anti-oxidative activity and can thus act as an anti-oxidant . Anti-oxidants are substances that slow or prevent the oxidative process caused by unstable oxidant (or oxidizing) molecules, such as free radicals or reactive oxygen species. The biological state in which the production of such oxidant molecules by bodily- systems or external sources overwhelms the natural anti-oxidative capacity is known as 'oxidative stress' . Oxidative stress can lead to cellular and tissue damage, and has been implicated as a contributory factor in many diseases and age-related disorders, for example, heart disease, macular degeneration, diabetes, cancer, and inflammatory disorders.
Other than health related implications, such oxidative processes can lead to deterioration in the
quality of products such as food, cosmetics and personal care products. For example, the oxidative processes can cause the development of rancidity and odour as well as discolouration of these products. Commercial production of capsaicin currently involves isolation of the compound from the plant raw material. Hence, commercial production of capsaicin is currently dependent on the quality, quantity and price of the crop. As capsaicin is only present in the plant in small quantities, isolation of the compound from the plant raw material is difficult and costly.
Other commercial anti-oxidants such as the synthetic chemicals butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) are volatile and decompose easily at high temperatures. Animal studies have also shown that BHT causes undesirable suppression of liver enzymes and enlargement of the liver.
Therefore, there is a need to provide anti-oxidative agents that overcome or at least ameliorate one or more of the disadvantages described above.
There is a need to provide anti-oxidative agents, such as novel capsaicin analogues and derivatives thereof, that exhibit potent anti-oxidative properties and reduced or no cytotoxic effects, and that can be easily produced in large quantities at low cost.
There is a need to provide novel capsaicin analogues and derivatives thereof for use in a medicament to treat and/or prevent oxidative stress related disorders, which have sufficiently low cytotoxicity such that they are not harmful to humans.
There is a need to provide novel capsaicin analogues and derivatives thereof for use as stabilizers in food, cosmetics and personal care products.
Summary
According to a first aspect, there is provided a compound represented by the general formula (I):
(D and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4 ;
Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group;
R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group;
Z is an oxygen (O) atom or sulfur (S) atom;
T is hydrogen or an optionally substituted aliphatic group;
with the proviso that when n = 2, Ri is not -OCH3 on the carbon-3 position of the phenyl group and Ri is not -OH on the carbon-4 position of the phenyl group.
According to a second aspect, there is provided a pharmaceutical or cosmetic composition comprising as an active ingredient a compound of formula (I) as defined herein and a pharmaceutically or cosmetically acceptable carrier.
According to a third aspect, there is provided a food preparation comprising a compound of formula (I) as defined herein.
According to a fourth aspect, there is provided a compound of formula (I) as defined herein for use in the prevention and/or treatment of a condition associated with oxidative stress and/or a condition caused by presence of free radicals.
According to a fifth aspect, there is provided use of a compound of formula (I) as defined herein, in the manufacture of a medicament for the prevention and/or treatment of a condition associated with oxidative stress and/or a condition caused by presence of free radicals.
According to a sixth aspect, there is provided a method of preventing and/or treating a condition in a subject, wherein the condition is associated with oxidative stress and/or caused by presence of free radicals, the method comprising administering to the subject an effective amount of a compound of Formula (I) as defined herein, or a pharmaceutically-acceptable salt thereof .
Definitions
The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.
Unless the context requires otherwise or specifically stated to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements. Those skilled in the art will also appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features . The term "analogue" refers to a compound which comprises a chemically modified form of a specific compound or- class thereof, and which maintains the chemical and/or biological activities that are characteristic of the specific compound and class. For example, the term "analogue" as used herein may be used to refer to a chemically modified form of a compound of
formula (I) which maintains the anti-oxidant properties of a compound of formula (I) .
The term "derivative" refers to any salt, solvate or prodrug, e.g. ester, of a compound of the invention, which upon administration to a subject, is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Preparation of such derivatives is routine to those skilled in the art without undue experimentation. The term "active compound" in connection with the present invention is understood as meaning a compound as disclosed herein which is capable of causing a required therapeutic or cosmetic effect in a patient or subject, for example an anti-oxidant effect. The terms "pharmaceutically acceptable salt" and "cosmetically acceptable salt" refer to those salts which retain the chemical and/or biological effectiveness and properties of the active compound, which are not otherwise undesirable. A thorough discussion of pharmaceutically and cosmetically acceptable salts is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991) .
The term "optionally substituted" as used herein means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from hydrogen, oxygen, sulfur, alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, carboxyl, haloalkyl, haloalkynyl, hydroxyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl,
nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocycloxy, heterocycloamino, haloheterocycloalkyl, alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphonyl and phosphinyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, cyano, cyanate, isocyanate, -C (0) NH (alkyl) , and
C(O)N(alkyl)2. The term "hydroxyl" as used herein refers to the functional group -OH.
The term "alkoxy" as used herein refers to straight chain or branched alkyloxy groups. Examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, and the like.
The term "thiol" means -SH.
The term "thioether" refers to ether groups wherein the oxygen is replaced with a sulfur. The thioether groups include but are not limited to -alkylene-S-alkyl, -alkylene-S-aryl, -alkylene-S-arylalkyl, -alkylene-S- alkylaryl, -aryl-S-alkyl , -aryl-S-aryl , -aryl-S- alkylaryl, -aryl-S-arylalkyl, -arylalkyl-S-alkyl, arylalkyl-S-aryl, -arylalkyl-S-alkylaryl, -arylalkyl-S- arylalkyl, -alkylaryl-S-alkyl, -alkylaryl-S-aryl, alkylaryl-S-alkylaryl, and -alkylaryl-S-arylalkyl . The thioether groups may be optionally substituted as described above.
The term "nucleophile" as used herein refers to a chemical moiety that has a reactive pair of electrons and that participates in a chemical reaction by donating electrons, i.e., nucleophiles are electron donor
compounds. The nucleophile may be a halogen, nitrogen, sulfur or oxygen nucleophile. Exemplary nucleophiles include fluorides, cyanides, iodides, chlorides, bromides, acetates, enolates, primary amines, secondary amines, amino, alkoxides, thiols, alkyl sulfides (such as mercaptans) , hydroxides, azides, and hydrazines, among others .
The term "amino" as used herein refers to groups of the form -NR3 or -NR3Rb wherein R3 and Rb are independently selected from the group including but not limited to hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy and optionally substituted aryl groups. For example, the term "amino" as used herein may be used to refer to an -NH group at the R2 and/or R3 position of a compound of formula (I) , or to an -NHCH3 group in the optionally substituted aliphatic group at the T position of a compound of formula (I).
The term "aliphatic" refers to a linear, branched, or cyclic alkyl, alkenyl, or alkynyl group.
The term "alkyl" includes within its meaning straight chain or branched chain saturated aliphatic groups having from 1 to 10 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. For example, the term alkyl includes, but is not limited to, methyl, ethyl, 1-propyl, isopropyl, 1-butyl, 2-butyl, isobutyl, tert-butyl, amyl, 1, 2-dimethylpropyl, 1, 1-dimethylpropyl, pentyl, isopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 2, 2-dimethylbutyl, 3,3- dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 1, 2, 2-trimethylpropyl, 1, 1, 2-trimethylpropyl, 2-
ethylpentyl, 3-ethylpentyl, heptyl, 1-methylhexyl, 2,2- dimethylpentyl, 3, 3-dimethylpentyl, 4, 4-dimethylpentyl, 1, 2-dimethylpentyl, 1, 3-dimethylpentyl, 1,4- dimethylpentyl, 1, 2, 3-trimethylbutyl, 1,1,2- trimethylbutyl, 1, 1, 3-trimethylbutyl, 5-methylheptyl, 1- methylheptyl, octyl, nonyl, decyl, and the like.
The term "lower alkyl" refers to a straight or branched saturated hydrocarbon chain having 1, 2, 3, 4, 5, or 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
The term "alkenyl" includes within its meaning straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms and having at least one double bond, of either E, Z, cis or trans stereochemistry where applicable, anywhere in the alkyl chain. Examples of alkenyl groups include but are not limited to ethenyl, vinyl, allyl, 1-methylvinyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl, 3-butentyl, 1,3- butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4- pentenyl, 1, 3-pentadienyl, 2, 4-pentadienyl, 1,4- pentadienyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 1, 3-hexadienyl, 1, 4-hexadienyl, 2- methylpentenyl, 1-heptenyl, 2-heptentyl, 3-heptenyl, 1- octenyl, 1-nonenyl, 1-decenyl, and the like.
The term "lower alkenyl" refers to a straight or branched saturated hydrocarbon chain having 2, 3, 4, 5, or 6 carbon atoms.
The term "alkynyl" as used herein includes within its meaning straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms and having at least one triple bond anywhere in the carbon chain. Examples of alkynyl groups include but are not limited to ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, l-methyl-2-butynyl, 3-methyl-l-butynyl, 1-pentynyl, 1- hexynyl, 1-methylpentynyl, 1-heptynyl, 2-heptynyl, 1- octynyl, 2-octynyl, 1-nonyl, 1-decynyl, and the like. The term "lower alkynyl" refers to a straight or branched saturated hydrocarbon chain having 2, 3, 4, 5, or 6 carbon atoms.
The term "heteroatom" or variants such as "hetero-" as used herein refers to oxygen (0) , nitrogen (N) , phosphorus (P) and sulfur (S) .
The term "aryl" or variants such as "aromatic group" or - "arylene" as used herein refers to single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms. Exemplary aryl groups include, but are not limited to phenyl, naphthyl, tetrahydronaphthyl, and the like.
The term "heteroaryl" and variants such as "heteroaromatic group" or "heteroarylene" as used herein, includes within its meaning single, polynuclear, conjugated and fused aromatic moieties having 5 to 20 atoms wherein 1 to 6 atoms are heteroatoms selected from 0, N, NH and S. Examples of such groups include pyridyl, 2, 2' -bipyridyl, phenanthrolinyl, quinolinyl, thiophenyl, indoyl, furanyl and pyrrolyl moieties and the like. The term "cycloalkyl" as used herein refers to cyclic saturated aliphatic groups and includes within its
meaning monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon moieties having from 3 to 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Examples of cycloalkyl groups include but are not limited to cyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, 2-methylcyclopentyl, 3-methylcyclopentyl, cyclohexyl, and the like.
The term "halide" or variants such as "halogen" or "halo" as used herein refers to fluoride, chloride, bromide and iodide.
The present invention includes within its scope all isomeric forms of the compounds disclosed herein, including all diastereomeric isomers, racemates and enantiomers. Thus, compounds of formula (I) and derivatives thereof should be understood to include, for example, E, Z, cis, trans, (R) , (S) , (L) , (D) , (+) , and/or (-) forms of the compounds, as appropriate in each case.
The term "oxidative stress" as used herein refers to damage to biological molecules resulting from oxidation including, but not limited to, oxidation of lipoproteins and membrane phospholipids; lipid peroxidation; protein damage, including cleavage of amino acid bonds and oxidation of functional groups; nucleic acid strand breaks; nucleic acid base modifications leading to point mutations; inhibition of RNA and protein synthesis; protein cross-linking; impaired maintenance of membrane ion gradients; and depletion of cellular levels of ATP, any of which may lead to cellular dysfunction and eventually to disease.
The term "anti-oxidative agent" or "anti-oxidant" refers to a compound having reducing or reductive activity or power, which may prevent the generation of oxidizing molecules such as free radicals and reactive oxygen species, and remove or inactivate such oxidizing molecules, thus preventing, delaying or minimizing oxidative stress, and the damage and deterioration resulting therefrom. Typically, such anti-oxidative agents remove or inactivate the oxidizing molecules by means of electron transfer from the anti-oxidative agent to the oxidizing molecule. Anti-oxidative agents disclosed herein have applications in the treatment of one or more oxidative stress related disorder as described below, and in prevention of deterioration in product quality (such as in food, cosmetic and personal care products) . Deterioration in product quality may be for example, development of rancidity and undesirable colour and odour.
The term "treatment" includes any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever. Hence, "treatment" includes prophylactic and therapeutic treatment.
The term "patient" or "subject" refers to patients or subjects of human or other mammal and includes any individual it is desired to examine or treat using the active compounds and methods disclosed herein. However, it will be understood that "patient" or "subject" does not imply that symptoms are present. Suitable mammals
that fall within the scope of the invention include, but are not restricted to, primates, livestock animals (eg. sheep, cows, horses, donkeys, pigs) , laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g. cats, dogs) and captive wild animals (e.g. foxes, deer, dingoes). "Mammal" refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, and pet companion animals such as a household pet and other domesticated animal such as, but not limited to, cattle, sheep, ferrets, swine, horses, poultry, rabbits, goats, dogs, cats and the like. Preferred companion animals are dogs and cats. Preferably, the mammal is human. The term "administering" and variations of that term including "administer" and "administration", includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, or a surface by any appropriate means. The term "effective amount" when used in relation to an anti-oxidative agent, refers to an amount sufficient to effect the desired anti-oxidative benefit. Similarly, the terms "therapeutically effective amount," "pharmaceutically effective amount" and "cosmetically effective amount" include within their meanings a sufficient but non-toxic amount of a compound or composition of the invention to provide the desired therapeutic or cosmetic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the
condition being treated, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "effective amount". However, for any given case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.
The term "dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a predetermined quantity of compound (s) is calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The compound (s) may be formulated for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the ingredients. Unless specified otherwise, the terms "comprising" and "comprise", and grammatical variants thereof, are intended to represent "open" or "inclusive" language such that they include recited elements but also permit inclusion of additional, unrecited elements. As used herein, the term "about", in the context of concentrations of components of the formulations, typically means +/- 5% of the stated value, more typically +/- 4% of the stated value, more typically +/- 3% of the stated value, more typically, +/- 2% of the stated value, even more typically +/- 1% of the stated
value, and even more typically +/- 0.5% of the stated value.
Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Certain embodiments may also be described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the disclosure. This includes the generic description of the embodiments with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
Detailed Disclosure of Embodiments
Exemplary, non-limiting embodiments of the active compounds having anti-oxidative activity will now be disclosed.
The inventors have found that the active compounds disclosed herein exhibit potent anti-oxidative activity with reduced or no cytotoxicity. Accordingly, the active compounds disclosed herein can be used as anti-oxidative agents in medicaments and health supplements to treat and/or prevent diseases or conditions associated with oxidative stress and/or caused by presence of free radicals, and in cosmetic products to produce an anti- oxidative effect for example an anti-aging effect. The active compounds disclosed herein can also be used as anti-oxidative agents to stabilize food, cosmetic and personal care products against deterioration.
The Active Compounds The active compounds may be represented by compound having the general formula (I) :
(0 and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4;
Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group;
R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group;
Z is an oxygen (0) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group; with the proviso that when n = 2, Ri is not -OCH3 on the carbon-3 position of the phenyl group and R1 is not -OH on the carbon-4 position of the phenyl group. n can be 1, 2, 3, 4 or 5.
In one embodiment, Z is an oxygen (0) atom.
In another embodiment, Z is not a sulfur (S) atom.
Advantageously, in embodiments where Z is an oxygen (0) atom instead of a sulfur (S) atom, the compounds of formula (I) exhibit high anti-oxidant activity and reduced or no cytotoxicity.
In one embodiment, n is between 1 to 3.
In a preferred embodiment, n is 2. In one embodiment where n is 2, Ri is on the carbon-3 position and the carbon-4 position of the phenyl group. In another embodiment where n is 2, Ri is on the carbon-2 position and the carbon-5 position of the phenyl group.
In one embodiment where n is 2, each of Ri is -OH. Preferably, in embodiments where n is 2 and each of Ri is -OH, one of Ri is on the carbon-3 position and the other Ri is on the carbon-4 position of the phenyl group.
In one embodiment, Z is an oxygen (0) atom, n is 2, and each of Ri is -OH.
In one embodiment, Z is not a sulfur (S) atom, n is 2, and each of Ri is -OH.
In one embodiment, n is 1 and Ri is on the carbon-4 position of the phenyl group. In another embodiment where n is 1, Ri is on the carbon-2 position of the phenyl group. p can be 0, 1, 2, 3 or 4.
In one embodiment, p is 1.
In one embodiment, Ri is OU wherein U is an alkyl group having from 1 to 6 carbon atoms.
In another embodiment, Ri is ZiTi, wherein Zi is a sulfur (S) atom or oxygen (O) atom and Ti is a lower alkyl group. The lower alkyl may have from 1 to 6 carbon atoms .
In yet another embodiment, Ri is independently selected from the group consisting of -OH, -OCH3, OCH2CH3, -OCH2CH2CH3, -OCH2CH2CH2CH3, -OCH2CH2CH2CH2CH3, - OCH2CH2CH2CH2CH2CH3, -SH, -SCH3, -SCH2CH3, -SCH2CH2CH3, - SCH2CH2CH2CH3, -SCH2CH2CH2CH2CH3 and -SCH2CH2CH2CH2CH2CH3.
In some embodiments where n is 2, 3, 4 or 5, all the Ri groups are the same. For example, where n is 2, both Ri groups may be -OH, both Ri groups may be -OCH3, both Ri groups may be OCH2CH3, both R1 groups may be -OCH2CH2CH3, both Ri groups may be -OCH2CH2CH2CH3, both Ri groups may be -OCH2CH2CH2CH2CH3, both Ri groups may be OCH2CH2CH2CH2CH2CH3, both R1 groups may be -SH, both Ri groups may be -SCH3, both Ri groups may be -SCH2CH3, both Ri groups may be -SCH2CH2CH3, both Ri groups may be - SCH2CH2CH2CH3, both Ri groups may be -SCH2CH2CH2CH2CH3, or both Ri groups may be -SCH2CH2CH2CH2CH2CH3.
In other embodiments where n is 2, 3, 4 or 5, each Ri group is different. For example, where n is 2, one Ri group may be -OH and the other Ri group may be
OCH2CH2CH3, or where n is 3, two Ri groups may be -OH and the third R1 group may be -OCH3 or the first Ri group may be -OH, the second R1 group may be -OCH3 and the third Ri group may be -OCH2CH2CH3. In one embodiment, n is 2 and one of Ri is -OH and the other of Ri is -OCH3.
In one embodiment, T is an aliphatic group with 1 to 20 carbons. In a preferred embodiment, T is an aliphatic group with 1 to 10 carbons. In a more preferred embodiment, T is an aliphatic group with 5 to 10 carbons.
In one embodiment, the aliphatic group of T is an alkyl, preferably a lower alkyl. The alkyl may be straight chain alkyl or a branched chain alkyl.
Preferably, the alkyl is a straight chain alkyl. The alkyl may be -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, - CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH2CH3, - CH2CH2CH2CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH2CH2CH2CH3 or CH(CH3)2.
In another embodiment, the aliphatic group of T is an aliphatic group containing at least one unsaturated alkenyl or alkynyl group, preferably lower alkenyl or lower alkynyl groups. Suitable alkenyl groups include - CHCH2, -CH2CHCH2, -CHCHCH3, and -CHCHCH3, while suitable alkynyl groups include -CCCH3, -CH2CCH, -CH2CH2CCH, CH2CH2CH2CCH, -CH2CH2CH2CH2CCH, and -CH2CCCH3.
In yet another embodiment, T is an aliphatic group substituted with one or more heteroatom groups. Suitable heteroatom groups include, without limitation, oxygen (0), sulfur (S), and nitrogen (N) and phosphorous (P). In yet another embodiment, T is an aryl group, heteroaryl group or cycloalkyl group, each optionally
substituted with one or more groups selected from hydrogen, oxygen, sulfur, alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, carboxyl, haloalkyl, haloalkynyl, hydroxyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocycloxy, heterocycloamino, haloheterocycloalkyl, alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphonyl, phosphinyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, cyano, cyanate, isocyanate, C(O)NH(alkyl) , and -C (0) N (alkyl) . In one embodiment, both R2 and R3 are methylene groups. In another embodiment, one of R2 and R3 is a methylene group and the other is a nucleophile. In yet another embodiment, both R2 and R3 are nucleophiles .
In one embodiment, the nucleophile of R2 and/or R3 is selected from the group consisting of a halide, a nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile .
Suitable halides include, but are not limited to, fluoride, chloride, bromide and iodide, and the like. Suitable nitrogen nucleophiles include, but are not limited to, amino groups (e.g. primary amino groups, secondary amino groups and tertiary amino groups) , and azides (e.g. metal azides of Li, Na or K), and the like.
Suitable sulfur nucleophiles include thiols and alkyl sulfides, and the like.
Suitable oxygen nucleophiles include acetates, enolates, alkoxides, and hydroxides, and the like.
The halide, nitrogen nucleophile, sulfur nucleophile and oxygen nucleophile may be optionally substituted as described above.
In one embodiment of the compounds described herein, the nucleophile of R2 and/or R3 is a nitrogen nucleophile.
In one embodiment, the nitrogen nucleophile is an amino group. The amino group may be a NH group, a NHV group or a NW group where V and V are each independently selected from the group consisting of a Ci-
C4 lower alkyl, a phenyl, and an alkoxy group.
In one embodiment, the compound has the formula (II):
In one embodiment, the compound has the formula (III) :
In one embodiment, the compound has the formula
(IV) :
In one embodiment, the compound has the formula
(VI) :
In one embodiment, the compound has the formula (VII) :
In one embodiment, the compound has the formula (VIII):
In one embodiment, the compound has the formula
:iχ)
In one embodiment, the compound has the formula
(XI) :
In one embodiment, the compound has the formula
(XII) :
In one embodiment, the compound has the formula (XIII) :
In one embodiment, the compound has the formula (XIV) :
In one embodiment, the compound has the formula
(XVI) :
In one embodiment, the compound has the formula
(XVII) :
In one embodiment, the compound has the formula
(XVIII) :
Since the disclosed active compounds may have asymmetric carbon centers, they can be present in the form of racemate, diastereomers or mixtures thereof. Therefore, the present invention also includes all these isomers and their mixtures.
Synthesis of Active Co∑apovmds
The disclosed active compounds having the general formula (I) may be prepared by a process as described below.
Generally, the active compounds are synthesized via nucleophilic substitution reactions. A nucleophile and a second reactant (an electrophile) are mixed in an anhydrous solvent, and stirred at room temperature to produce the active compounds. The active compounds are extracted with an organic solvent, and the resulting organic extracts are concentrated under reduced pressure to give a crude product.
The nucleophile is an amine having a formula (Ia) , or a hydrochloride or hydrobromide salt thereof having a formula (Ia') as shown below:
(Ia) (Ia') where R is H or CH3, Y is N or CH, and X is Cl or Br. Alternatively, the nucleophile is a straight chain amine having a formula (Ia"):
H2N
(Ia") where n is 1 or 3. The electrophile is an acid chloride (such as a nonanoyl chloride) , an isocyanate or isothiocyanate, or a lactone .
The nucleophile and the electrophile are typically used in a stoichiometric ratio, but the excess of one component or the other may be advantageous.
The anhydrous solvent is N, N-dimethylformamide (DMF) , dichloromethane or tetrahydrofuran.
Where the nucleophile used is a hydrochloride or hydrobromide salt of an amine having a formula (Ia' ) , N,N-diisopropylethylamine (DIPEA) can be added to liberate the amine group. Where the electrophile used is a lactone, 2- hydroxypyridine is added as a reaction catalyst.
Typically, the mixture is stirred at room temperature for 6 to 24 h before being extracted with an organic solvent such as dichloromethane. The organic extract is concentrated under reduced pressure to give a crude active compound, which is then purified using silica gel column chromatography or preparative high performance liquid chromatography.
Active Compound Salts
In some forms, it may be desirable to formulate the active compounds in pharmaceutically or cosmetically acceptable salt form, generally to improve the solubility and bioavailability and to provide an active compound that may be capable of being assimilated readily. Preferably, the pharmaceutically or cosmetically acceptable salts are suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
The active compounds may form pharmaceutically or cosmetically acceptable salts with both organic and inorganic acids. Suitable physiologically tolerated acids for salt formation may be organic and inorganic acids, such as hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric,
succinic, ascorbic, maleic, methanesulfonic, isethionic, lactic, gluconic, glucuronic, sulfamic, benzoic, tartaric, pamoic, and the like.
The salts may be prepared by contacting a free base form with an equivalent amount of the desired acid in the conventional manner. The free base forms may be regenerated by treating the salt form with a base. For example, dilute aqueous base solutions may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions may be suitable for this purpose.
The free base forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvent. Otherwise, the salts may be equivalent to their respective free base forms for purposes of the invention.
The active compounds may exist in unsolvated as well as solvated forms, including hydrated forms. Such salt forms of the active compound may be provided or mixed prior to use with a physiologically acceptable solvent such as water or ethanol.
Therapeutic Uses of Active Compounds
Use as Ant±-ox±dat±ve Agents
It has been found that the active compounds of general formula (I) have potent anti-oxidant activity, and reduced or no cytotoxicity. Hence, the disclosed active compounds may be capable of stopping or preventing oxidative stress in a subject. Accordingly, the
disclosed active compounds may be envisaged as being useful for use as anti-oxidative agents in the treatment, prevention, inhibition or amelioration of one or more oxidative stress related disorders or condition, and/or conditions caused by presence of free radicals in a subject.
(a.) Use in Medicine
Subjects having or at risk of developing an oxidative stress related disorder include those having inflammatory disorders, autoimmune disorders such as rheumatoid arthritis, lupus and neurodegenerative disease such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS) , atherosclerosis, cerebral ischemia, hepatopathy, diabetes, nervous diseases, renal diseases, hepatic cirrhosis, arthritis, retinopathy of prematurity, ocular uveitis, retinal rust disease, senile cataract, asbestos diseases, bronchial failures due to smoking, cerebral edema, pulmonary edema, foot edema, cerebral infarction, coronary artery disease, hemolytic anemia, progeria, epilepsy, Crohn's disease, Kawasaki disease, collagen disease, progressive systemic sclerosis, herpetic dermatitis, immune deficiency syndrome or the like.
Such subjects may benefit from the anti-oxidative effect of the active compounds disclosed herein, when administered in pure form or with one or more other ingredient in a pharmaceutical composition as discussed below. Hence, the active compounds may be provided as a
pharmaceutical composition in the form of a medicament as discussed below.
(b) Use in Health Supplements and Cosmetic Formulations
Another aspect of using the active compounds as anti-oxidative agents is on the preventive side. Instead of waiting for the free radicals to make a long chain of free radicals and cause oxidative damage to cells and tissues, the active compounds scavenge and destroy the initiating free radicals before oxidation is set in motion, to thereby delay the onset and progress of the aging process and prevent onset of an oxidative stress related disease.
Hence, the active compounds disclosed herein may be provided in pure form or with one or more other ingredients in a health supplement. Alternatively, the active compounds may be provided in pure form or with one or more other ingredients in a cosmetic formulation as discussed below.
Pharmaceutical Compositions
The active compounds for use as an anti-oxidative agent may be administered in pure form or in an appropriate pharmaceutical composition. In general, suitable pharmaceutical compositions may be prepared according to methods which are known to those of ordinary skill in the art. The compositions comprising the active compounds disclosed herein may include a conventional
pharmaceutical carrier or diluent, and in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc. Examples of suitable pharmaceutical carriers or diluents include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Other suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences (Mack Publishing Company) , a standard reference text in this field, or in U.S. Pharmacopeia National Formulary, 1857-1853, (1990). Typically, the carrier(s) or diluent (s) will form from about 10% to about 99.9% by weight of the compositions.
Administration of the active compounds disclosed herein, in pure form or in an appropriate pharmaceutical composition, may be carried out via any of the acceptable modes of administration or pharmaceutically acceptable means of delivery. The modes of administration and pharmaceutically acceptable means of delivery may include oral administration or delivery in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms. The dosage forms may include tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
Oral administration of the disclosed active compounds may be effected by preparing a mixture of the disclosed active compounds with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be
compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the disclosed active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations may contain the active compounds in an amount by weight percent selected from the group consisting of about 0.1% to about 70%, about 0.5% to about 65%, about 1% to about 60%, about 2% to about 55% and about 3% to about 50%.
The tablets, troches, pills, capsules and the like may also contain the following: a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup of elixir may contain sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavorings, such as cherry or orange flavor. Any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
In addition, the active compounds may be incorporated into sustained-release preparation and formulations.
The active compounds disclosed herein may be administered parenterally or intraperitoneally . Solutions of the disclosed active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose . Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use may include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms may be brought about by various antibacterial and antifungal agents, for example,
parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Prolonged absorption of the injectable compositions can also be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.
Preferably, the pharmaceutical form may further include a suitable buffer to minimise acid hydrolysis.
Suitable buffer agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.
The active compounds may also be administered in the form of a "prodrug". A prodrug is an inactive form of a compound which is transformed in vivo to the active form.
Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.
The active compounds in pharmaceutically acceptable form may be administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compounds employed; the metabolic stability and length of action of the compounds; the age, body weight, general health, sex and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disease states; and the patient undergoing treatment.
Single or multiple administrations of the pharmaceutical compositions according to the invention may be carried out. One skilled in the art would be able, by routine experimentation, to determine effective, non- toxic dosage levels of the compound and/or composition of the invention and an administration regime which would be
suitable for treating the diseases and/or conditions to which the compounds and compositions are applicable.
It will be apparent to one of ordinary skill in the art that the optimal course of treatment, such as the number of doses of the compound or composition of the invention given per day for a defined number of days, can be ascertained using conventional course of treatment determination tests.
Generally, an effective dosage per 24 hours for use of the active compounds as anti-oxidative agents in a pharmaceutical composition may be in the range of about 0.5 mg per kg body weight to about 10 mg per kg body weight; suitably, about 1 mg per kg body weight to about 6 mg per kg body weight. Alternatively, an effective dosage may be up to about 20 mg per kg body weight. For example, generally, an effective dosage is expected to be in the range of about 10 to about 20 mg per kg body weight .
The active compounds of the invention may be used in combination with other known treatments or anti-oxidative agents. Combinations of active agents, including the active compounds of the invention, may be synergistic.
Cosmetic Formulations
The active compounds disclosed herein may also be used to provide anti-oxidative effect in the form of cosmetic formulations such as anti-aging creams, lipstick, face cream, body lotion, moisture creams, burn remedies containing local anesthetics and the like. The active compounds have protective effect against damage to
the skin that is induced by UV light, and hence prevent damage caused by radiation from natural or artificial sources such as the sun, either alone or in combination with sunscreen agents such as PABA. The active compounds may be used individually or in combination with one or more other ingredients in the cosmetic formulation, such as solvents, emollients, humectants, emulsifiers, surfactants, thickeners, coloring agents, preservatives (such as anti-bacterial agents, anti-viral agents, anti-fungal agents) , vitamins, antibiotics, anti-inflammatory agents, anti-acne agents, anti-irritants, anti-dandruff agents, anti-perspirants, anti-wrinkle agents, whitening agents, moisturizing agents, and fragrances, among others. Cosmetically acceptable ingredients and formulations are also discussed in, for example, FDA Cosmetics Handbook, U.S. Food and Drug Administration; Handbook of Cosmetic and Personal Care Additives, Ash and Ash, compilers, 1994, Chemical Publishing, New York, N . Y . ; and Remington's Pharmaceutical Sciences, 18.sup.th ed., Gennaro, ed., 1990, Mack Publishing.
The active compounds are "cosmetically acceptable" in terms of being compatible with the other ingredients of the cosmetic formulation, and not deleterious to the recipient thereof.
The cosmetic formulations to which the active compounds may be added are preferably in a form suitable for topical administration, although cosmetic preparations in a form suitable for administration by parenteral injection (such as subcutaneous, intramuscular or intravenous injection), oral ingestion (such as
capsules, tablets, caplets and elixirs) , or inhalation
(such as by intranasal inhalation or oral inhalation) are also envisaged. Topical formulations, preferably hypoallergenic and pH-controlled, include liquid or semi- liquid preparations such as lotions or liniments, creams, ointments or pastes, drops, tinctures, salves, patches, powders and solutions containing the active compounds disclosed herein and one or more cosmetically acceptable carriers, and optionally any other ingredients as discussed above.
Methods for preparing topical, injectable, oral and aerosol compositions comprising the active compounds disclosed herein and other ingredients described above are apparent to those skilled in the art, and are described in, for example, Remington 's Pharmaceutical Science, 15th ed. , Mack Publishing Company, Easton, Pa.
The dosage, frequency and duration of administration of a cosmetic formulation comprising the disclosed active compounds is dependent on factors including the nature of the formulation (for example, its concentration, the presence or lack of other active ingredients, and the delivery system used) , the severity and extent of the condition being treated, the form, route and site of administration, the discretion of the individual being treated, and in some cases, the judgment of a skin care professional (for example, a dermatologist or a cosmetologist). The dosage, frequency and duration required to achieve a cosmetic effect can be readily determined by one of ordinary skill in the art. Typical effective dosages are expected to be in the range of about 0.01 μg/mL to about 2 mg/mL. Typically,
the active compounds are used in an amount of about 0.01 μg/mL to about 1.5 mg/mL, about 0.01 μg/mL to about 1 mg/mL, about 0.01 μg/mL to about 100 μg/mL, about 0.01 μg/mL to about 10 μg/mL, about 0.01 μg/mL to about 1 μg/mL, about 0.1 μg/mL to about 2 mg/mL, about 1 μg/mL to about 2 mg/mL, about 10 μg/mL to about 2 mg/mL, about 100 μg/mL to about 2 mg/mL, about 1 mg/mL to about 2 mg/mL or about 1.5 mg/mL to about 2 mg/mL.
Typical frequencies of administration are expected to be about once, twice, three times, four times, five times, or six times per week, or about once, twice, three times, four times, five times, or six times per day. In some embodiments, the administration is carried out about once to about three times per day. In some embodiments, the administration is carried out about twice to about four times per day. In some embodiments, the administration is carried out more than about three times per day. Where administration is carried out twice per day, the administration is typically in the morning and in the evening.
Non-therapeutic Uses of Active Coxcpoimcis
Food, cosmetic and personal care products are susceptible to oxidative damage, which can adversely affect the flavour, odour and colour of the product, making them less appealing to consume or use. Antioxidants can stabilize such products against oxidation and thereby improve their quality and storage potential.
(A) Use as Stabilizers in Food
The most common molecules attacked by oxidation are unsaturated fats. Oxidation causes unsaturated fats to turn rancid, resulting in discolorization and development of unpleasant tastes. Hence, it is important to avoid oxidation in oil- and fat-rich foods. The term ΛVfood" and "food product" as used herein refers to any edible substance for human consumption as well as feed for animal consumption (e.g. pet food, animal feed). Accordingly, edible substances suitable for human or animal consumption that may be stabilized against oxidation using the active compounds disclosed herein include, but are not limited to, frying oils and fats such as tallow, lard, peanut oil, corn oil, cottonseed oil, olive oil, safflower oil, soybean oil, coconut oil, shortening, cooking oils, salad oils and dressings; potato flakes; bakery products; meat emulsions; precooked cereals; instant noodles; soybean milk; chicken products; emulsion products such as sausage; mayonnaise and margarine; frozen fish; frozen pizza; cheese and animal foods. The oils and fats may be naturally-occurring, such as animal or vegetable fats, or synthetic materials.
The active compounds disclosed herein may be used in an amount based on the weight of the edible substance, which amount is effective as an anti-oxidant , that is an amount sufficient to stabilize, or retard the deterioration of, the edible substances to be stored and used to prepare foods in a normal and acceptable manner. Typically, the amount of the active compound employed is any amount which may have a significant stabilizing
effect, and may depend on various factors, such as the desired period of stability of the edible substance, the rate of deterioration of the edible substance, the type of oxidation to be stabilized against, and the type of edible substance etc. For example, when a prolonged storage life of the edible substance before use is desired, increased amounts of the active compounds may be used. Typically, the active compounds are used in an amount of about 0.001% to about 5%, of about 0.005% to about 5%, of about 0.01% to about 5%, of about 0.05% to about 5%, of about 0.1% to about 5%, of about 0.5% to about 5%, of about 1% to about 5%, of about 2% to about 5%, of about 3% to about 5%, of about 4% to about 5%%, of about 0.001% to about 4%, of about 0.001% to about 3%, of about 0.001% to about 2%, or of about 0.001% to about 1%, by weight based on the weight of the edible substance.
The active compounds disclosed herein may be used in pure form or in combination with one or more other antioxidants to achieve desirable combinations of properties of stability. For example, the active compounds disclosed herein may be used in combination with one or more of the phenolics (e.g. BHA and BHT); tocopherols
(e.g. α-tocopherol, β-tocopherol, γ-tocopherol, δ- tocopherol and mixtures thereof) ; benzylphosphonates (e.g. dimethyl-2, 5-di-tert-butyl-4-hydroxybenzylphos- phonate and diethyl-3, 5-di-tert-butyl-4-hydroxy- benzylphosphonate) ; esters of (3, 5-di-tert-butyl-4- hydroxyphenyl) propionic acid, (5-tert-butyl-4-hydroxy-3- methylphenyl) propionic acid, (3, 5-dicyclohexyl-4- hydroxyphenyl) propionic acid or 3, 5-di-tert-butyl-4- hydroxyphenyl acetic acid with mono- or polyhydric
alcohols; ascorbic acid (vitamin C) ; phosphites and phosphonites (e.g. triphenyl phosphite, diphenyl alkyl phosphites, phenyl dialkyl phosphites etc.); and rosemary extract, among others. The active compounds may also be used in combination with one or more other food additives such as emulsifiers (e.g. mono- and di-glycerides of saturated or unsaturated fatty acids such as monoglyceryl palmitate, polyoxyethylene derivatives of hexahydric alcohols such as sorbitol, glycols, glycol esters, polyglycerol esters, sorbitan esters, stearoyl lactylate, acetic acid esters, lactic acid esters, citric acid esters, acetylated monoglyceride, diacetyl tartaric acid esters, polyoxyethylene sorbitan esters such as polysorbate 80, sucrose esters, lecithin, egg yolk, and mixtures thereof) , suspension agents and colorings to provide the desired qualities in the final food product.
Preferably, the presence of the active compounds disclosed herein does not materially affect the manner in which the edible substance is formulated or in which it is used to prepare food or food products. The active compounds may be added at the time of food preparation or may be premixed with the edible fat or fatty oils to stabilize them prior to food preparation. Preferably, the active compounds are uniformly admixed in the edible substance. The active compounds disclosed herein are suitable for use in both small-scale and large-scale production of food and food products.
(B) Use as Stabilizers in Cosmetic and Personal Care Products
The active compounds disclosed herein are also suitable for stabilizing cosmetic and personal care products, particularly fat-based cosmetic and personal care products, against oxidative damage that can cause rancidity and product discoloration. Cosmetic and personal care products that may be stabilized by the active compounds include those that may be applied to any part of the human body, such as skin, hair or nails. Exemplary cosmetic and personal care products include, but are not limited to, lipsticks and other lip care products, make-up, foundations, facial masks, detergents, hair colorants, liquid soaps, bar soaps, creams, lotions, bath gels, hand cleaners, facial cleansers, exfoliants, sunscreens, conditioners, shampoos, shaving creams, hair detanglers, hot oil treatments, toilet waters, and fabric softeners, and the like. Typically, the amount of the active compound employed is any amount which may have a significant stabilizing effect, and may depend on various factors, such as the desired period of stability of the cosmetic o'r personal care product, the rate of deterioration of the cosmetic or personal care product, the type of oxidation to be stabilized against, and the type of the cosmetic or personal care product. Typically, the active compounds are used in an amount of about 0.001% to about 5%, of about 0.005% to about 5%, of about 0.01% to about 5%, of about 0.05% to about 5%, of about 0.1% to about 5%, of about 0.5% to about 5%, of about 1% to about 5%,
of about 2% to about 5%, of about 3% to about 5%, of about 4% to about 5%%, of about 0.001% to about 4%, of about 0.001% to about 3%, of about 0.001% to about 2%, or of about 0.001% to about 1%, by weight based on the weight of the cosmetic or personal care product.
The active compounds may be used in pure form or in combination with one or more other ingredients in the cosmetic and personal care product, such as solvents, emollients, humectants, emulsifiers, surfactants, thickeners, coloring agents, preservatives (such as antibacterial agents, anti-viral agents, anti-fungal agents), vitamins, antibiotics, anti-inflammatory agents, antiacne agents, anti-irritants, anti-dandruff agents, anti- perspirants, anti-wrinkle agents, whitening agents, moisturizing agents, and fragrances, among others. Suitable ingredients and formulations are also discussed in, for example, FDA Cosmetics Handbook, U.S. Food and Drug Administration; Handbook of Cosmetic and Personal Care Additives, Ash and Ash, compilers, 1994, Chemical Publishing, New York, N. Y.; and Remington's Pharmaceutical Sciences, 18.sup.th ed. , Gennaro, ed. , 1990, Mack Publishing. Methods for preparing topical, injectable, oral and aerosol compositions suitable for use in cosmetic and personal care products comprising the active compounds disclosed herein and other ingredients described above are apparent to those skilled in the art, and are described in, for example, Remington's Pharmaceutical Science, 15th ed. , Mack Publishing Company, Easton, Pa. One skilled in the art will recognize in light of the present disclosure that although the specified
materials and conditions are important in practicing the invention, unspecified materials and conditions are not excluded as long as they do not prevent the benefits of the invention from being realized.
Brief Description of Drawings
The accompanying drawings illustrate a disclosed embodiment and serves to explain the principles of the disclosed embodiment. It is to be understood, however, that the drawings are designed for purposes of illustration only, and not as a definition of the limits of the invention. Fig. 1 shows the dose response curve of analogue JC017 in cytotoxicity assays using A549 and HepG2 cell lines .
Fig. 2 shows the dose response curve of analogue JC058 in cytotoxicity assays using A549 and HepG2 cell lines.
Fig. 3 shows a comparison of the cytotoxicity of analogues JC017 and JC058 in a cytotoxicity assay using the A549 cell line.
Fig. 4 shows a comparison of the cytotoxicity of analogues JC017 and JC058 in a cytotoxicity assay using the HepG2 cell line.
Examples
Non-limiting embodiments of the disclosed active compounds will be further described in greater detail by
reference to specific Examples, which should not be construed as in any way limiting the scope of the invention.
Synthesis of Capsaicin Analogues
Materials
The chemical reagents and solvents used in the following examples were purchased from Sigma-Aldrich and Merck.
Analytical Protocols
(a) Analytical High Performance Liquid Chromatography (HPLC)
Analytical HPLC was performed on a Waters HPLC system equipped with a Waters 2998 PDA detector, Waters 2695 separation module using a Phenomenex Luna C18(2) (4.6 mm I. D. * 150 mm, 5μ) column. A gradient elution starting with 20% CH3CN, 80% (0.1% formic acid/H2O) , and ending with 100% CH3CN at a flow rate of 1.0 mL/min over 15 min was used.
(b) Preparative HPLC Preparative HPLC was performed on a Shimadzu LC-8A HPLC system equipped with a CBM-20A PDA detector, Gilson 215 liquid handler and fraction collector using a X- Bridge Prep Cis (30 mm I. D. * 50 mm, 5μ) column. An isocratic elution with 20% CH3CN, 80% (0.1% formic acid/H2O) at a flow rate of 20.0 mL/min for 5 min was used. This was followed by a gradient elution starting
with 20% CH3CN, 80% (0.1% formic acid/H2O) , and ending with 100% CH3CN at a flow rate of 20.0 mL/min over 45 min.
(c) Liquid Chromatography-Mass Spectrometry (LC-MS)
LC-MS data was collected on a Shimadzu LCMS-IT-TOF instrument equipped with SPD-M20A PDA detector, LCMS-IT- TOF MS detector and LC-20AD binary gradient pump using a Shimpack VP-ODS (2.0 mm I. D. * 150 mm) column. An isocratic elution with 20% H2O and 80% CH3CN at a flow rate of 0.2 mL/min over 3 min was used.
Example 1 : Synthetic Procedure for Analogues JC004, JC005 and JCOIl
To a solution of the hydrochloride or hydrobromide salt of an amine (1 mmol) in anhydrous N,N- dimethylformamide (DMF) (2 mL) was added N, N- diisopropylethylamine (DIPEA) (2 mmol) to liberate the amine. After stirring at room temperature for 10 min, nonanoyl chloride (1 mmol) was added. The solution was stirred at room temperature for 6 to 24 h. After the reaction, water (40 mL) was added to the solution. The reaction mixture was transferred to a separating funnel and extracted with dichloromethane, CH2Cl2 (3 * 6 mL) . The organic extracts were concentrated under reduced pressure
to give a crude product. The crude product was then purified by silica gel column chromatography (using hexane/ethyl acetate, 2:1 v/v, as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product.
Example 2: Synthetic Procedure for Analogues JCOOl, JC008 and JC013
To a solution of amine (1 mmol) in anhydrous dichloromethane or W/2V-dimethylformamide (DMF) (2 mL) were added _V,iV-diisopropylethylamine (DIPEA) (1 mmol) and nonanoyl chloride (1 mmol). The solution was stirred at room temperature for 6 to 24 h. After the reaction, water (20 mL) was added to the solution. The reaction mixture was transferred to a separating funnel and extracted with dichloromethane, CH2CI2 (3 * 10 mL) . The organic extracts were concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (using hexane/ethyl acetate, 2:1 v/v, as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product.
Example 3: Synthetic Procedure for Analogues JC006, JC007, JCOlO, JC014, JC015, JC017 and JC058
To a solution of the hydrochloride or hydrobromide salt of an amine (1-2 mmol) in anhydrous dichloromethane, tetrahydrofuran or N,Λ7-dimethylformamide (DMF) (2-4 mL) was added N,N-diisopropylethylamine (DIPEA) (1-2 iranol) to liberate the amine. After stirring at room temperature for 10 min, isocyanate or isothiocyanate (1-2 mmol) was added. The solution was stirred at room temperature for 6 to 24 h. After the reaction, water (20 mL) was added to the solution. The reaction mixture was transferred to a separating funnel and extracted with dichloromethane, CH2CI2 (3 * 10 mL) . The organic extracts were concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (using hexane/ethyl acetate, 2:1 v/v, as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product.
For analogues that precipitated during the extraction process with dichloromethane, the suspension containing the precipitated analogues was transferred to a Falcon tube and centrifuged. The supernatant was discarded. The pellet was re-suspended with ethyl acetate
(5 mL) and centrifuged. The re-suspension and centrifugation steps were carried out twice. The crude product obtained was further purified by preparative HPLC
(using the protocol set out in "Analytical Protocols" above) .
Example 4: Synthetic Procedure for Analogues JC003, JC009, JC012, JC016 and JC018-JC022
To a solution of an amine (1-2 ramol) in anhydrous dichloromethane, tetrahydrofuran or N, N-dimethylformamide (DMF) (2-4 mL) was added isocyanate or isothiocyanate (1- 2 mmol) . The solution was stirred at room temperature for 6 to 24 h. After the reaction, water (20 mL) was added to the solution. The reaction mixture was transferred to a separating funnel and extracted with dichloromethane, CH2CI2 (3 * 10 mL) . The solvent extracts were concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (using hexane/ethyl acetate, 2:1 v/v, as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product.
For analogues that precipitated during the extraction with dichloromethane, the suspension containing the precipitated analogues was transferred to a Falcon tube and centrifuged. The supernatant was discarded. The pellet was re-suspended with ethyl acetate (5 mL) and centrifuged. The re-suspension and centrifugation steps were carried out twice. The crude product obtained was further purified by preparative HPLC
(using the protocol set out in "Analytical Protocols" above) .
gχaτnp2e 5: Synthetic Procedure for Analogues JC023-JC026
To a solution of lactone (2 mmol) and 2- hydroxypyridine (0.2 mmol) in anhydrous dichloromethane (5 mL) was added an amine (2.2 mmol) . The mixture was stirred at room temperature for 6 to 24 h. After the reaction, water (20 mL) was added. The reaction mixture was transferred to a separating funnel and extracted with dichloromethane, .CH2Cl2 (3 * 10 mL) . The solvent extracts were concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (using hexane/ethyl acetate, 1:1 v/v as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product .
Example 6: Analytical Data on Capsaicin Analogues
The capsaicin analogues prepared in Examples 1-5 above were analyzed using the analytical protocols set out above. The resulting mass spectral, yield and purity data for each analogue are tabulated in Table 1 below.
Table 1 . Analytical Data on Capsaicin Analogues
Total anti-oxidant activity can be measured using various assays that are based on different reaction mechanisms. These include the Oxygen Radical Absorbance Capacity (ORAC) assay, the Total Radical Trapping Antioxidant Parameter (TRAP) assay, the Total Equivalent Anti-oxidant Capacity (TEAC) assay, and the 2, 2-Diphenyl- 1-picrylhydrazyl Radical Scavenging Capacity (DPPH) assay. On the basis of chemical principles, the ORAC assay is closely related to the biological functions of chain-breaking anti-oxidants and has been used extensively in anti-oxidant studies. Hence, the ORAC assay was used to test the anti-oxidant activities of the capsaicin analogues prepared in Example 1-5 above.
The DPPH assay is also a simple and accurate method for measuring anti-oxidant levels. The DPPH assay was used as a comparison to the ORAC assay for obtaining additional information on the reducing power of the test samples (Mahattanatawee et al., 2006, J. Agric. Food Chem. 54, 7355-7363) .
Materials 2, 2' -azobis (2-methylpropionamidine) dihydrochloride
(AAPH), 2,2-Diphenyl-l-picrylhydrazyl (DPPH) and resazurin were purchased from Sigma-Aldrich. Fluorescence natrium was purchased from Merck and Trolox was purchased from Acros. All measurements were carried out with Tecan Infinite 200.
ORAC Assay
The ORAC assay is based on the free radical damage caused to a fluorescent probe. In general, the assay applies a thermal peroxyl radical (R00») generator, the azo compound 2, 2 ' -azobis (2-amidinopropane) dihydrochloride (AAPH) , to give a steady flux of peroxyl radicals in an air-saturated solution. The loss of fluorescence intensity of a fluorescein probe is an indication of the extent of the damage resulting from its reaction with the peroxyl radical. The protective effect of an anti-oxidant is measured by assessing the area under the fluorescence decay curve (AUC) of the sample as compared to that of the blank in which no anti-oxidant is present (Ou et al., 2001, J. Agric. Food Chem. 49, 4619- 4626).
The ORAC assay was performed as described by Huang et al (Huang et al., 2002. J. Agric. Food Chem. 50, 4437-4444) with some minor modifications. Firstly, the capsaicin analogues were dissolved in methanol and added in volumes of 10 μl/well into a black 96-well plate in duplicate or triplicate with serial dilutions. 150 μl of 80 nM fluorescein was then added to the 96-well plate, followed by the addition of 40 μl of 100 mM AAPH (2,2'- azobis (2-amidinopropane) dihydrochloride). The plate was read immediately after addition of the AAPH at two minute intervals at an excitation wavelength of 485 nM and an emission wavelength of 535 nM at 37°C for 2 hours.
The template of a 96-well plate in an ORAC assay is as follows:
10 11 12
In wells A1-H9, 10 μl/well of the test sample, 150 μl/well of 80 nM fluorescein and 40 μl /well 100 mM AAPH were added. In wells AlO-HIl, a Trolox serial dilution was prepared with methanol starting at a final assay concentration of 100 μM. The concentrations in the serial dilution were 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, 1.563 μM and 0.781 μM. A series of 10 μl/well of Trolox, 150 μl 80 nM fluorescein and 40 μl/well 100 mM AAPH were prepared in duplicate.
In wells A12-H12, methanol 10 μl/well, 150 μl/well 80 nM fluorescein and 40 μl/well 10OmM AAPH were added to provide the Blank reading.
Data Processing:
The ORAC values were calculated according to Huang et al. (supra) . The net area under the curve (AUC) of the Trolox standard and the test samples were also calculated using the following equation:
AUC = O.5+(R2/R1)+(R3/R1)+(R4/R1)+ + 0.5(Rn/Rl) (Eq. 1)
where Rl is the fluorescence reading at the initiation of the reaction and Rn is the final measurement.
The Net AUC was calculated using the following equation:
Net AUC = AUCsample - AUCblank (Eq. 2.)
When net AUC values were calculated from these kinetic curves and plotted against Trolox concentration, a linear relationship was observed. The standard curve was interpolated to determine the readings of the unknown test samples. The relative Trolox equivalent ORAC value is expressed as μmol TE / μmol capsaicin analogue. A higher Trolox equivalent value would imply a higher antioxidant activity.
DPPH Assay DPPH is one of a few stable and commercially available organic nitrogen radicals and has an absorption maximum at 517 nm. The ability of a compound to scavenge stable [DPPH]* is a widely used method for evaluating Radical-Scavenging Capacity (RSC) in a relatively short time compared to other methods. Upon reduction, the colour of the solution fades as illustrated by the following chemical reaction:
DPPH 517nm (purple)
The progress of the reaction is easily monitored by a spectrophotometer (Molyneux, 2004; Eklund et al., 2005; and Shama et al. , 2009) .
The DPPH assay was modified and carried out with a 9β-well plate (Molyneux, 2004; Eklund et al., 2005; Shama et al., 2009). A 190 μl/well DPPH solution (150 μM) in methanol was mixed with a 10 μl/well sample dissolved in methanol. The progress of the reaction was monitored by determining the absorbance of the mixture at 517 nm after 30 min.
The template of a 96-well plate in a DPPH assay is as follows:
In wells All-Hll, 10 μl/well methanol and 190 μl/well 150 μM DPPH were added as negative controls.
In wells A12-H12, 200 μl/well methanol were added to provide the Blank reading.
Data Processing: The percentage of the DPPH scavenging activity was calculated as based on the following equation:
(Eq. 3)
The percentage of the" remaining [DPPH]* is proportional to the anti-oxidant concentration, and the concentration that scavenges 50% of the initial [DPPH]* is defined as EC50.
Cytotoxicity Assay
The cytotoxicity assay was conducted using the HepG2 (human hepatocellular carcinoma, ATCC HB-8065) and A549 (human lung carcinoma, ATCC CCL-185) cell lines. The assay is based on the use of an indicator dye resazurin to measure the metabolic capacity of a cell. A viable cell would retain the ability to reduce resazurin to resorufin, which is a highly fluorescent compound.
Conversely, a non-viable cell would rapidly lose its metabolic capacity, and hence would not reduce the resazurin to generate the fluorescent resorufin signal.
100 μL of lOVmL HepG2 or A549 cells was added to each well in a 96-well plate. The cells were incubated at 37°C overnight. On the second day, 10 μL of the test sample was then added to each well and the mixture incubated for 24 h at 37°C. On the third day, 20 μL of 1.8 mg/mL resazurin were added to each well and the mixture incubated for 4 h at 37°C. The plate was then read at an excitation wavelength of 535 nm and an emission wavelength of 590 nm with a Tecan Infinite 200 microplate reader.
The template of the 9β-well plate used in a cytotoxicity assay was similar to the template used in the DPPH assay, except that 10% DMSO was used as the solvent for the test sample and controls. The data was also processed using the same equation as in the DPPH assay (i.e. Eq. 3) .
Example 7: Anti-oxidant Activity of Capsaicin Analogues
The anti-oxidant activities of the various capsaicin analogues prepared in Examples 1-5 above were determined using the ORAC and DPPH assays. The anti-oxidant activities of the various analogues are shown in Table 2 below.
Table 2 . Anti-oxidant Activities of Capsaicin Analogues
Comparative Examples
Comparative Example 1
Comparison of Anti-oxidant Activity of Capsaicin Analogues and Capsaicin
Capsaicin analogues with differing levels of anti- oxidant activity were prepared and analyzed as set out in Examples 1-7 above.
From Table 2, it can be seen that, of all the analogues, the analogue JC017 demonstrated the most potent anti-oxidant activity. The anti-oxidant activity of JC017 was 6.3 μmol TE/ μmol in the ORAC assay and the EC50 was 40 μM in the DPPH. In comparison, the antioxidant activity of capsaicin was about 3.3 μmol TE / μmol in the ORAC assay and the EC50 was 69 μM in the DPPH assay. Analogues JC014, JC016, JC018, JC022 and JC026 exhibited similar antioxidant activities to capsaicin in the ORAC assay. The activities of these analogues in the ORAC assay ranged from 3.4 μmol TE /μmol to 3.9 μmol TE /μmol. In the DPPH assay, the EC50 of analogues JC014, JC018 and JC026 ranged from 30 μM to 89 μM, which is similar to the EC50 of capsaicin. However, analogues JC016 and JC022 did not exhibit any nitrogen radical- scavenging activity in the DPPH assay.
The analogues JC004, JC005, JC006, JC007, JCOlO, JCOIl, JC012, JC023, JC024 and JC025 showed moderate activity ranging from 1.3 μmol TE/ μmol to 2.5 μmol TE/ μmol in the ORAC assay. In the DPPH assay, JC004, JC005, JC006, JC007, JCOlO, JCOIl and JC025 exhibited activities with EC50 values ranging from 28 μM to 178 μM while JC012, JC023 and JC024 did not exhibit any activity in the DPPH assay.
The analogues JC013, JC015 and JC021 exhibited minor anti-oxidant activity of 0.2 μmol TE / μmol, 0.5 μmol TE / μmol and 0.6 μmol TE / μmol respectively in the ORAC assay. None of these analogues exhibited any activity in the DPPH assay.
None of the capsaicin analogues tested demonstrated cytotoxicity at concentrations of up to 350 μM except for analogues JC024, JC025 and JC026, which exhibited slight cytotoxicity in HepG2 cell lines. JC024 and JC026 having IC50 values of 304 μM and 254 μM respectively, were less cytotoxic when compared to capsaicin, which has an IC50 of 178 μM in HepG2 cell lines. JC025 having an IC50 of 125 μM was slightly more cytotoxic than capsaicin.
In addition, the capsaicin analogues" disclosed herein, particularly analogues JC005, JC006, JC007, JCOlO, JCOIl, JC012, JC013, JC014, JC015, JC016, JC017, JC018, JC022, JC023, JC024, JC025 and JC026, were easily obtained through a simple synthetic procedure at a reduced cost compared to the high cost of isolating capsaicin from chili pepper. Those capsaicin analogues with no cytotoxicity can be used as potent anti-oxidative agents in medicine, health supplements, cosmetic
formulations, and stabilizers in food, cosmetics and personal care products.
Comparative Example 2 Comparison of Anti-oxidant Activity and Cytotoxicity of
Analogues JCO17 and JC058
Analogues JC017 and JC058 were synthesized based on the procedure set out in Example 3 above. Analogue JC058 has the same structure as analogue JC017 except that the oxygen at the λZ' position of formula (I) is replaced with a sulfur in JC058. The structures of both analogues are shown in Table 3 below.
The anti-oxidant activities of both analogues JC058 and JC017 were analyzed using the ORAC and DPPH assays as set out above. The cytotoxicity of both analogues JC058 and JC017 were also assayed using the HepG2 and A549 cell lines according to the protocol set out above.
The anti-oxidant activities and cytotoxicity of both analogues are set out in Table 3 below.
From Table 3 above, the anti-oxidant activities of the two analogues appear to be comparable. However, from a comparison of the cytotoxicity of the two analogues, analogue JC017 clearly exhibits significantly lower cytotoxicity than analogue JC058 in both the HepG2 cell line as well as in the A549 cell line. Hence, the data indicates that substitution of the sulfur atom on the carbonyl group of analogue JC058 with an oxygen atom in analogue JC017 confers the advantage of reducing the cytotoxocity of the compound while maintaining high antioxidant activity.
The dose response curves for analogue JC017 in a cytotoxicity assay using the cell lines HepG2 and A549 are shown in Fig. 1 while the dose response curves for analogue JC058 in a cytotoxicity assay using the cell lines HepG2 and A549 are shown in Fig. 2.
As can be seen from Fig. 1, when analogue JC017 was administered at varying concentrations to the HepG2 cell line, cell inhibition was relatively low, and ranged, on average, from 0% to about 40% after exposing the cell lines to varying concentrations of between 0.02 mM and 1.5 mM analogue JC017 for 24 hours. The IC50 of JC017 in the HepG2 cell line was higher than 1.5 mM.
In the dose-response curve of analogue JC017 in cytotoxicity assays on the A549 cell line for the same dosage range, there was no detectable cell inhibition even when doses of 1.5 mM were administered for 24 hours (Fig. 1) . The IC50 of JC017 in the A549 cell line was also higher than 1.5 mM. When analogue JC058 was administered at varying concentrations to the HepG2 and A549 cell lines, cell
inhibition showed a dose-response from concentrations of as low as 0.18 mM (Fig. 2). Cell inhibition as high as >90% was seen for a concentration of 1.5 mM after a 24- hour exposure to analogue JC058. The IC50 value of JC058 was 0.5 mM in the A549 cell line and 0.9 mM in the HepG2 cell line.
The dose-response curves for analogues JC017 and JC058 against the A549 cell line were compared in Fig. 3. It can be seen that, in the same concentration range, there was no detectable cell inhibition by analogue JC017, while the analogue JC058 showed high cell inhibition of upto >90% after a 24-hour exposure to 1.5 mM of JC058 (Fig. 3) In other words, analogue JC017 is not cytotoxic while analogue JC058 has comparatively high cytotoxicity.
Similarly, in a comparison of the dose-response curves for analogues JC017 and JC058 against the HepG2 cell line, it can be seen that cell inhibition by analogue JC017 was significantly lower than cell inhibition by analogue JC058 within the same concentration range tested (Fig. 4). In other words, analogue JC017 is less cytotoxic than analogue JC058.
In summary, analogues JC017 and JC058 both have comparably high anti-oxidant activity. Analogue JC017 has the added advantage of having low cytotoxicity.
Applications
The active compounds disclosed herein have demonstrated strong anti-oxidative activity. Advantageously, by providing strong anti-oxidative effect, the disclosed active compounds are useful as anti-oxidative agents. Accordingly, the disclosed active compounds are useful as anti-oxidative agents in medicines to treat a patient suffering from an oxidative stress related disorder or condition. The disclosed active compounds are also useful as anti-oxidative agents in health supplements and cosmetic formulations to prevent and delay aging caused by oxidative stress. The disclosed active compounds are furthermore useful as anti-oxidative agents for stabilizing food, cosmetics and personal care products against oxidative damage.
In addition, the disclosed active compounds have very low toxicity to humans and therefore are ideal for use in medicine, particularly for use in medicines for treating patients suffering from oxidative stress related disorders.
It will be apparent that various other modifications and adaptations of the invention will be apparent to the person skilled in the art after reading the foregoing disclosure without departing from the spirit and scope of the invention and it is intended that all such modifications and adaptations come within the scope of the appended claims.
Claims
1. A compound represented by the general formula (D :
(0 and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4 ; Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group;
R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group;
Z is an oxygen (O) atom or sulfur (S) atom;
T is hydrogen or an optionally substituted aliphatic group; with the proviso that when n = 2, Ri is not -OCH3 on the carbon-3 position of the phenyl group and Ri is not -OH on the carbon-4 position of the phenyl group.
2. A compound as claimed in claim 1, wherein Z is an oxygen (0) atom.
3. A compound as claimed in claim 1 or 2, wherein n is between 1 to 3.
4. A compound as claimed in any one of the preceding claims, wherein n is 2.
5. A compound as claimed in any one of the preceding claims, wherein n is 2 and Ri is on the carbon-3 position and the carbon-4 position of the phenyl group.
6. A compound as claimed in any one of claims 1 to 4, wherein n is 2 and Ri is on the carbon-2 position and the carbon-5 position of the phenyl group.
7. A compound as claimed in any one of the preceding claims, wherein n is 2 and each of Ri is -OH.
8. A compound as claimed in any one of claims 1 to 3, wherein n is 1 and Ri is on the carbon-4 position of the phenyl group.
9. A compound as claimed in any one of claims 1 to 3, wherein n is 1 and Ri is on the carbon-2 position of the phenyl group.
10. A compound as claimed in any one of the preceding claims, wherein p is 1.
11. A compound as claimed in any one of the preceding claims, wherein Ri is OU, wherein U is an alkyl group having from 1 to 6 carbon atoms.
12. A compound as claimed in any one of the preceding claims, wherein Ri is ZiTi, wherein Zi is a sulfur (S) atom or oxygen (0) atom and Ti is a lower alkyl group.
13. A compound as claimed in claim 12, wherein the lower alkyl has from 1 to 6 carbon atoms.
14. A compound as claimed in claims 1-6 and 8-13, wherein Ri is independently selected from the group consisting of -OH, -OCH3, -OCH2CH3,
OCH2CH2CH3, -OCH2CH2CH2CH3, -OCH2CH2CH2CH2CH3, OCH2CH2CH2CH2CH2CH3, -SH, -SCH3, -SCH2CH3, SCH2CH2CH3, -SCH2CH2CH2CH3, -SCH2CH2CH2CH2CH3, and - SCH2CH2CH2CH2CH2CH3.
15. A compound as claimed in claim 14, wherein n is 2 and one of Ri is -OH and the other of Ri is -OCH3.
16. A compound as claimed in any one of the preceding claims, wherein T is an aliphatic group with 1 to
20 carbons.
17. A compound as claimed in claim 16, wherein T is an aliphatic group with 1 to 10 carbons.
18. A compound as claimed in claim 17, wherein T is an aliphatic group with 5 to 10 carbons.
19. A compound as claimed in any one of the preceding claims, wherein the aliphatic group of T is an alkyl.
20. A compound as claimed in claim 19, wherein the alkyl of T is straight or branched chain.
21. A compound as claimed in any one of claims 1 to 18, wherein the aliphatic group of T is an aliphatic group containing at least one unsaturated alkenyl or alkynyl group.
22. A compound as claimed in any one of the preceding claims, wherein T is an aliphatic group substituted with heteroatoms groups.
23. A compound as claimed in any one of claims 1 to 15, wherein T comprises an optionally substituted aryl group, heteroaryl group or cycloalkyl group.
24. A compound as claimed in any one of the preceding claims, wherein the nucleophile of R2 and/or R3 is selected from the group consisting of a halide, a nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile.
25. A compound as claimed in claim 24, wherein the nitrogen nucleophile is an amino group.
26. A compound as claimed in claim 25, wherein the amino group is selected from the group consisting of NH, NHV and NW' where V and v' are each independently selected from the group consisting of a C1-C4 lower alkyl, a phenyl, and an alkoxy group.
27. A compound as claimed in any one of the preceding claims, selected from the group consisting of:
28. A pharmaceutical or cosmetic composition comprising as an active ingredient a compound of any one of the preceding claims and a pharmaceutically or cosmetically acceptable carrier.
29. A food preparation comprising a compound as claimed in any one of claims 1 to 27.
30. A compound of any one of claim 1 to 27 for use in the prevention and/or treatment of a condition associated with oxidative stress and/or a condition caused by presence of free radicals.
31. Use of a compound of any one of claims 1 to 27, in the manufacture of a medicament for the prevention and/or treatment of a condition associated with oxidative stress and/or a condition caused by. presence of free radicals.
32. A method of preventing and/or treating a condition in a subject, wherein said condition is associated with oxidative stress and/or caused by presence of free radicals, said method comprising administering to said subject an effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 27.
33. The compound of claim 30, the use of claim 31, or the method of claim 32, wherein said condition is selected from the group consisting of aging, coronary heart disease, cardiovascular disease, cancer, stroke, neurodegenerative disease, inflammatory conditions, respiratory disease, digestive disease, hepatic disease, immune disease and diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0909768.4A GB0909768D0 (en) | 2009-06-08 | 2009-06-08 | Novel compounds and uses thereof |
GB0909768.4 | 2009-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010144055A1 true WO2010144055A1 (en) | 2010-12-16 |
Family
ID=40937017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2010/000216 WO2010144055A1 (en) | 2009-06-08 | 2010-06-07 | Novel compounds and uses thereof |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0909768D0 (en) |
WO (1) | WO2010144055A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2499666A (en) * | 2012-02-27 | 2013-08-28 | Nanyang Polytechnic | Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders |
CN105395531A (en) * | 2015-12-04 | 2016-03-16 | 徐迅迪 | Application of 8-methyl-N-vanillyl-trans-6-nonenamide in preparing medicine for treating liver cancer |
CN105732412A (en) * | 2016-03-10 | 2016-07-06 | 陕西中医药大学 | Amide compound for treating stroke and preparation method thereof |
CN109160927A (en) * | 2017-09-21 | 2019-01-08 | 暨南大学 | New amides compound and its application in moringa seeds |
CN116003276A (en) * | 2022-12-22 | 2023-04-25 | 上海化学试剂研究所有限公司 | Method for synthesizing capsaicin by utilizing micro-reaction chip |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424205A (en) * | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
EP0068590B1 (en) * | 1981-06-30 | 1985-01-02 | THE PROCTER & GAMBLE COMPANY | Novel urea derivatives |
US5356894A (en) * | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
US20030139470A1 (en) * | 2000-06-23 | 2003-07-24 | Ley Jakob Peter | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants |
WO2004071445A2 (en) * | 2003-02-11 | 2004-08-26 | Pharmacopeia Drug Discovery, Inc. | 2-(aminomethyl)arylamide analgesics |
WO2005049620A1 (en) * | 2003-11-20 | 2005-06-02 | Astrazeneca Ab | Novel compounds |
WO2006078239A1 (en) * | 2005-01-18 | 2006-07-27 | University Of Florida | Compositions and methods for inhibiting pain |
WO2007109783A2 (en) * | 2006-03-23 | 2007-09-27 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US20090143397A1 (en) * | 2006-08-07 | 2009-06-04 | Lotus Pharmaceutical Co., Ltd. | Catechol-based derivatives for treating or preventing diabetics |
-
2009
- 2009-06-08 GB GBGB0909768.4A patent/GB0909768D0/en not_active Ceased
-
2010
- 2010-06-07 WO PCT/SG2010/000216 patent/WO2010144055A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0068590B1 (en) * | 1981-06-30 | 1985-01-02 | THE PROCTER & GAMBLE COMPANY | Novel urea derivatives |
US4424205A (en) * | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
US5356894A (en) * | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
US20030139470A1 (en) * | 2000-06-23 | 2003-07-24 | Ley Jakob Peter | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants |
WO2004071445A2 (en) * | 2003-02-11 | 2004-08-26 | Pharmacopeia Drug Discovery, Inc. | 2-(aminomethyl)arylamide analgesics |
WO2005049620A1 (en) * | 2003-11-20 | 2005-06-02 | Astrazeneca Ab | Novel compounds |
WO2006078239A1 (en) * | 2005-01-18 | 2006-07-27 | University Of Florida | Compositions and methods for inhibiting pain |
WO2007109783A2 (en) * | 2006-03-23 | 2007-09-27 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US20090143397A1 (en) * | 2006-08-07 | 2009-06-04 | Lotus Pharmaceutical Co., Ltd. | Catechol-based derivatives for treating or preventing diabetics |
Non-Patent Citations (2)
Title |
---|
GARLE ET AL.: "Stimulation of dichlorofluorescin oxidation by capsaicin and analogues in RAW 264 monocyte/ macrophages: Lack of involvement of the vanilloid receptor", BIOCHEMICAL PHARMACOLOGY, vol. 59, 2000, pages 563 - 572 * |
ROSA ET AL.: "Antioxidant activity of capsinoids", JOURNAL OF AGRICULTURE AND FOOD CHEMISTRY, vol. 50, 2002, pages 7396 - 7401, XP002388560, DOI: doi:10.1021/jf020431w * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2499666A (en) * | 2012-02-27 | 2013-08-28 | Nanyang Polytechnic | Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders |
CN105395531A (en) * | 2015-12-04 | 2016-03-16 | 徐迅迪 | Application of 8-methyl-N-vanillyl-trans-6-nonenamide in preparing medicine for treating liver cancer |
CN105732412A (en) * | 2016-03-10 | 2016-07-06 | 陕西中医药大学 | Amide compound for treating stroke and preparation method thereof |
CN109160927A (en) * | 2017-09-21 | 2019-01-08 | 暨南大学 | New amides compound and its application in moringa seeds |
CN109160927B (en) * | 2017-09-21 | 2020-09-22 | 暨南大学 | Novel amide compounds in moringa seeds and application thereof |
CN116003276A (en) * | 2022-12-22 | 2023-04-25 | 上海化学试剂研究所有限公司 | Method for synthesizing capsaicin by utilizing micro-reaction chip |
Also Published As
Publication number | Publication date |
---|---|
GB0909768D0 (en) | 2009-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010144055A1 (en) | Novel compounds and uses thereof | |
HU197735B (en) | Process for producing ascorbinic acid derivatives and pharmaceutical compositions containing them | |
JP6321788B2 (en) | Production of (S, S) -secoisolaricylesinol diglucoside and (R, R) -secoisolaricylesinol diglucoside | |
WO2018122789A1 (en) | Hydroxybenzoic acid derivatives, methods and uses thereof | |
CZ20032396A3 (en) | Dimeric isoflavones | |
CN102421788A (en) | A process for the preparation of phytosteryl ferulate | |
RU2041208C1 (en) | Derivatives of 3,3′-dithiobis-(propionic acid) or their stereoisomers and composition showing immunomodulating action | |
Bellotti et al. | Synthesis, structural characterization and effect on human granulocyte intracellular cAMP levels of abscisic acid analogs | |
KR101366372B1 (en) | New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof | |
EP3319950B1 (en) | Vicinal primary diamines associated with metal and/or free radical chelation motifs, and active against carbonyl and oxidative stress, and use thereof | |
DE69016914T2 (en) | PHOSPHOLIPID DERIVATIVES. | |
DE2625688C3 (en) | 1,3-Diphenoxypropanol- (2) derivatives and processes for their preparation and their use as pharmaceuticals | |
KR100556157B1 (en) | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | |
CA1299182C (en) | Eicosatetraynamides and their use in pharmaceutical and cosmetic products | |
AU2010204706A1 (en) | Compositions and methods of use | |
JP2009062314A (en) | Autoimmune disease-treating agent | |
EP4292593A1 (en) | Pharmaceutical composition for preventing cytokine storm | |
KR101931442B1 (en) | A novel compound having anti-oxidant or anti-inflammatory activity | |
KR20200022628A (en) | Phenylacetic acid derivatives and composition for preventing or treating autoimmune diseases comprising the same | |
KR101488583B1 (en) | New compounds having skin whitening activity and medical use thereof | |
KR101491728B1 (en) | Conjugate of vitamin C with vitamin B3 and antioxidant comprising the same | |
JPS5835505B2 (en) | N-(α-methyl-benzyl)-fatty acid amide | |
US7943599B2 (en) | Sesamol derivatives or their salts, the process for preparing the same, and the skin external composition containing the same | |
WO2012116577A1 (en) | Chlorogenic acid analogue, preparation process and use thereof | |
KR101334466B1 (en) | New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10786468 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10786468 Country of ref document: EP Kind code of ref document: A1 |